Protocol Number: VPED-103 
Official Title: A Phase 1, Randomized , Parallel-group , Open-label , Multicen ter Study to Evaluate 
the Pharmacokinetics , Pharmacodynamics and Safety of Vonoprazan (10 or 20 mg Once Daily) in 
Children Aged ≥ 6 to < 12 Years Who Have Symptomatic Gastroesophageal Reflux Disease 
Study ID: [REMOVED]  
Document Date: 31 Aug 2023
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 3 Protocol Approval – Principal/Coordinating Investigator  
Study Title  A Phase 1, Randomized, Parallel -group, Open -label, Multicenter 
Study to Evaluate the Pharmacokinetics, Pharmacodynamics and 
Safety of V onoprazan (10 or 20 mg Once Daily) in Children Aged  ≥ 6 
to < 12 Years Who Have Symptomatic Gastroesophageal Reflux Disease  
Protocol Number VPED -103 
Protocol Version 
and Date Amendment 2 
30 August 2023 
Protocol
 accepted and approved by: 
Principal/Coordinating Investigator  
 
 
 
 
 
 
Signature  Date  
31-Aug-2023

Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 4 Declaration of Investigator  
I have read and understood all sections of the protocol entitled “A Phase 1, Randomized, 
Parallel -group, Open-label, Multicenter Study to Evaluate the Pharmacokinetics, 
Pharmacodynamics and Safety of V onoprazan (10 or 20 mg Once Daily) in Children Aged ≥ 6 to < 12 Years Who Have Symptomatic Gastroesophageal Reflux Disease” and the 
accompanying investigator’s brochure. 
I agree to supervise all aspects of the protocol and to conduct the clinical investigation in 
accordance with the Final Protocol Amendment 2, dated 30 August 2023, the International Council for Harmonisation harmonised tripartite guideline E6(R2): Good Clinical Practice, 
and all applicable government regulations. I will not make changes to the protocol before 
consulting with Phathom Pharmaceuticals, Inc. or implement protocol changes without Institutional Review Board/Independent E thic Committee approval except to eliminate an 
immediate risk to subjects. I agree to administer study drug only to subjects under my personal supervision or the supervision of a subinvestigator. 
I will not supply the investigational drug to any person not authorized to receive it. 
Confidentiality will be protected. Subject identity will not be disclosed to third parties or 
appear in any study reports or publications. 
I will not disclose information regarding this clinical investigation or publish results o f the 
investigation without authorization from Phathom Pharmaceuticals, Inc. 
 
    
Signature of Principal Investigator   Date  
 
 
   
Printed Name of Principal Investigator    
 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 5 Table of Contents  
Table of Contents .......................................................................................................................5  
List of Tables  ..............................................................................................................................8  
List of Figures ............................................................................................................................9  
Protocol Synopsis.....................................................................................................................10  
List of Abbreviations ................................................................................................................14  
1 Introduction ......................................................................................................................16  
1.1 Study Rationale .......................................................................................................16  
1.2 Background .............................................................................................................16  
1.2.1  Epidemiology, Symptoms, and Current Treatments for GERD ...............16  
1.2.2  V onoprazan ..............................................................................................17  
1.3 Justification for Dose ..............................................................................................19  
2 Study Objectives and Endpoints ......................................................................................21  
3 Investigational Plan  ..........................................................................................................22  
3.1 Study Design ...........................................................................................................22  
3.1.1  Rationale of Study Design .......................................................................24  
4 Subject Selection and Withdrawa l Criteria  ......................................................................26  
4.1 Selection of Study Population .................................................................................26  
4.1.1  Inclusion Criteria  .....................................................................................26  
4.1.2  Exclusion Criteria  ....................................................................................27  
4.1.3  Screen Failures  .........................................................................................29  
4.2 Withdrawal of Subjects From Study Drug and/or the Study ..................................29  
4.2.1  Reasons for Withdrawal/Discontinuation ................................................29  
4.2.2  Handling of Withdrawals  .........................................................................31  
4.2.3  Lost to Follow-up.....................................................................................31  
4.2.4  Replacements  ...........................................................................................32  
5 Study Drugs ......................................................................................................................33  
5.1 Method of Assigning Subjects to Treatment Groups ..............................................33  
5.2 Treatments Administered  ........................................................................................33  
5.3 Identity of Investigational Product..........................................................................34  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 6 5.4 Management of Clinical Supplies ...........................................................................34  
5.4.1  Study Drug Packaging and Storage .........................................................34  
5.4.2  Study Drug Accountability ......................................................................34  
5.5 Overdose Management  ...........................................................................................35  
5.5.1  Treatment of Overdose ............................................................................35  
5.6 Blinding...................................................................................................................35  
5.7 Study Compliance ...................................................................................................35  
5.7.1  Treatment Compliance  .............................................................................35  
5.8 Prior and Concomitant Therapy ..............................................................................36  
5.8.1  Excluded Medications..............................................................................37  
6 Study Assessments and Procedures ..................................................................................38  
6.1 Pharmacokinetic and Pharmacodynamic Assessments ...........................................38  
6.1.1  Pharmacokinetic Assessments  .................................................................38  
6.1.2  Pharmacodynamic Assessments  ..............................................................40  
6.2 Efficacy Assessments  ..............................................................................................41  
6.2.1  GERD Symptom Assessment -Investigator ..............................................41  
6.3 Safety Assessments  .................................................................................................41  
6.3.1  Pretreatment Events and Adverse Events  ................................................41  
6.3.1.1  Definitions  ...............................................................................................41  
6.3.1.2  Documenting Adverse Events  ..................................................................48  
6.3.1.3  Time Period and Frequency for Collecting AE and SAE Information ....50  
6.3.1.4  Regulatory Reporting Requirements for SAEs ........................................53  
6.3.2  Pregnancy .................................................................................................54  
6.3.3  Laboratory Analyses  ................................................................................55  
6.3.4  Physical Examinations .............................................................................56  
6.3.5  Vital Signs  ................................................................................................57  
6.3.6  Electrocardiograms  ..................................................................................57  
6.4 Safety Monitoring Committee  ................................................................................57  
7 Statistical and Analytical Plan  ..........................................................................................58  
7.1 Sample Size Calculations  ........................................................................................58  
7.2 Analysis Sets  ...........................................................................................................58  
7.3 Statistical Analysis Methodology  ...........................................................................58  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 7 7.3.1  Pharmacokinetic Analyses  .......................................................................58  
7.3.2  Pharmacodynamic Analyses  ....................................................................58  
7.3.3  Efficacy Analyses  ....................................................................................59  
7.3.4  Safety Analyses  ........................................................................................59  
7.3.5  Interim Analyses  ......................................................................................59  
8 Data Quality Assurance  ....................................................................................................60  
8.1 Data Management  ...................................................................................................60  
9 Ethics  ................................................................................................................................61  
9.1 Institutional Review Board or Independent Ethics Committee ..............................61  
9.2 Ethical Conduct of the Study ..................................................................................61  
9.3 Subject Information and Consent............................................................................61  
10 Investigator’s Obligations ................................................................................................63  
10.1  Confidentiality  ........................................................................................................63  
10.2  Financial Disclosure and Obligations .....................................................................63  
10.3  Investigator Documentation ....................................................................................64  
10.4  Study Conduct .........................................................................................................64  
10.5  Adherence to Protocol.............................................................................................65  
10.6  Adverse Events and Study Report Requirements  ...................................................65  
10.7  Investigator’s Final Report .....................................................................................65  
10.8  Records Retention  ...................................................................................................65  
10.9  Publications .............................................................................................................65  
11 Study Management ...........................................................................................................67  
11.1  Monitoring ..............................................................................................................67  
11.1.1  External Data Monitoring Committee  .....................................................67  
11.1.2  Monitoring of the Study ...........................................................................67  
11.1.3  Inspection of Records ..............................................................................67  
11.2  Management of Protocol Amendments and Deviations..........................................68  
11.2.1  Modification of the Protocol ....................................................................68  
11.2.2  Protocol Deviations..................................................................................68  
11.3  Study Termination ...................................................................................................68  
11.4  Final Report ............................................................................................................69  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 8 12 Reference List ...................................................................................................................70  
13 Appendices .......................................................................................................................73  
13.1  Appendix 1: Schedule of Events .............................................................................73  
13.2  Appendix 2: Contraceptive Guidance .....................................................................75  
13.3  Appendix 3: Liver Function Tests ...........................................................................77  
13.3.1  Liver Function Test Monitoring ...............................................................77  
13.3.2  Considerations for Temporary Discontinuation of Study Drug ...............77  
13.3.3  Permanent Discontinuation of Study Drug ..............................................78  
13.3.4  Re-initiation of Study Drug .....................................................................79  
13.4  Appendix 4: Questionnaires ....................................................................................80  
13.4.1  GERD Symptom Assessment -Investigator ..............................................80  
13.5  Appendix 5: Tanner Staging ...................................................................................82  
13.6  Appendix 6: National Center for Health Statistics Clinical Body Weight Charts 
with 5th and 95th Percentiles  ............................................................................83  
13.6.1  Girls  .........................................................................................................83  
13.6.2  Boys .........................................................................................................84  
13.7  Appendix 7: Protocol Amendments ........................................................................85  
13.7.1  Protocol Amendment 1  ............................................................................85  
13.7.2  Protocol Amendment 2  ..........................................................................121  
 
List of Tables  
Table  2-1  Study Objectives and Endpoints ..................................................................... 21  
Table  5-1  Excluded Medications and Treatments ........................................................... 37  
Table  6-1  Pharmacokinetic Parameters to be Estimated using V onoprazan Plasma 
Concentration Data ......................................................................................... 40  
Table  6-2  Medically Significant Adverse Event List  ...................................................... 43  
Table  6-3  Adverse Events of Special Interest List  .......................................................... 44  
Table  6-4  Protocol- Required Safety Laboratory Assessments  ........................................ 56  
Table  13-1  Abnormal Liver Function Criteria for Permanent Discontinuation of Study Drug  ................................................................................................................ 78
 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 9 Table  6-4  Protocol- Required Safety Laboratory Assessments  ...................................... 125  
 
List of Figures  
Figure 3-1  Study Scheme.................................................................................................. 23  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 10 Protocol Synopsis  
Protocol Number:  VPED -103 
Title:  A Phase 1, Randomized, Parallel -group, Open- label, Multicenter Study 
to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of 
V onoprazan (10 or 20 mg Once Daily) in Children Aged ≥ 6 to < 12 Years Who Have Symptomatic Gastr oesophageal Reflux Disease  
Sponsor:  Phathom Pharmaceuticals, Inc.  
2150 East Lake Cook Road, Suite 800 Buffalo Grove, IL 60089 USA 
EU Trial Number:  2022-003228-42 
Study Phase:  1 
Study Sites:  Approximately 20 to 25 sites in the United States and Europe  
Indication:  Symptomatic gastroesophageal reflux disease (GERD) 
Rationale: GERD is prevalent globally and represents one of the most common gastrointestinal diseases. Per the Montreal definition, GERD is a condition that develops when the reflux of stomach contents causes 
troublesome symptoms and/or complications. The term GERD covers a 
spectrum of conditions, including symptomatic non- erosive GERD 
(sGERD), erosive esophagitis (EE), and Barrett's esophagus. The prevalence of GERD increases with age, from 2.5% of children 
between 3 and 9 years of age to 8.5% of those between 10 and 17 years 
of age. Similarly, the overall prevalence of EE increases with age, from 
5.5% in infants to 12.4% in children and adolescents. Younger children 
usually pr esent with extraesophageal manifestations, regurgitation, and 
epigastric pain, while older children and adolescents typically present with adult-type GERD symptoms of heartburn and regurgitation. Pediatric GERD is a condition that is not always outgrown and can manifest itself as a chronic disease.  
V onoprazan belongs to a new class of acid-inhibitory agents called “potassium- competitive acid blockers. ” In the United States, 
vonoprazan in combination with amoxicillin and in combination with amoxicillin and clarithromycin is approved for the treatment of Helicobacter pylori  
infection in adults. V onoprazan is being developed 
in adults for the treatment of heartburn in patients with symptomatic non-erosive GERD, healing of all grades of EE and relief of heartbu rn 
and maintenance of healing of all grades of EE and relief of heartburn. 
The pediatric doses for this study were selected to approximate equivalent adult exposures following administration of vonoprazan 10 or 20 mg QD to children ≥ 6 to < 12 years of age . 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 11 Objectives:  Primary:  
• To evaluate the pharmacokinetic profile of vonoprazan (10 or 
20 mg once daily [QD]) in children ≥ 6 to < 12 years of age who have symptomatic GERD. 
Safety:  
• To evaluate the safety of vonoprazan (10 or 20 mg QD) in 
children ≥ 6 to < 12 years of age who have symptomatic 
GERD.  
Exploratory: 
• To evaluate symptom relief and pharmacodynamics of vonoprazan (10 or 20 mg QD) in children ≥ 6 to < 12 years of age who have symptomatic GERD. 
Study Population:  Children ≥ 6 to < 12 years of age who have symptomatic GERD, with 
or without EE. 
Study Design and Interventions:  This is a Phase 1, uncontrolled, randomized, open- label, parallel -group, 
multiple -dose study in children ≥ 6 to < 12 years of age who have 
symptomatic GERD. Subjects will be scree ned for up to 28 days. 
Successfully screened subjects will be randomized to receive 10 or 20 mg of vonoprazan QD for 14 days. Approximately 18 subjects are expected to be enrolled in the study. 
Blood samples for pharmacokinetic testing will be collected on Days 7 and 14. Select sites will perform gastric pH monitoring in subjects deemed clinically indicated by the principal investigator.  
Subjects undergoing gastric pH monitoring will be confined to the 
clinic for testing. Gastric pH will be monitored for 2 4 hours beginning 
on Day -1 and on Day 7. 
The study will include 3 periods: 
Screening Period (≤ 4 weeks):  Subjects will undergo screening 
assessments to determine study eligibility, and baseline assessments 
will be performed. If all eligibility criteria are met, the subject will be randomized and enter the Treatment Period.  
Treatment Period (Day 1 to Day 14):  Subjects will be randomized to 
receive vonoprazan 10 mg or vonoprazan 20 mg QD. 
Follow -up Period:  A safety follow-up phone call will occur 2 weeks 
after the last dose of study drug to assess adverse events (AEs). 
A subject will be considered to have completed the study if the subject 
completes the Treatment Period and the safety follow -up phone call. 
Following the last dose of study drug or early discontinuation, the 
subject will be transitioned to local standard of care in accordance with 
each site’s prespecified process.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 12 Estimated Study 
Duration: The total duration of the study is up to 8 weeks. The Screening Period 
is up to 4 weeks, Treatment Period is 2 weeks, and safety follow-up 
phone call is 2 weeks after last study drug administration. 
Pharmacokinetic  
Assessments (Primary Endpoints):  The primary vonoprazan pharmacokinetic endpoints will include the following steady state paramete rs from data collected on Day 7 and 
Day 14: 
• Maximum observed drug concentration at steady state (C
max,ss) 
• Area under the plasma concentration -time curve during the 
dosing interval τ ( AUC τ) 
• Apparent oral clearance (CL/F)  
• Apparent volume of distribution (V z/F) 
Efficacy and 
Pharmacodynamic Assessments (Exploratory Endpoints):  Efficacy and pharmacodynamic characteristics will be assessed by the 
following: 
• The severity of GERD symptoms at screening and Days 7 and 14 as assessed by the investigator 
• Mean pH and percentage of time above pH 4, 5, and 6 at Day -1 and Day 7 in the subset of subjects for whom intragastric pH monitoring is performed when clinically indicated per the investigator 
Safety Assessments 
(Safety Endpoints):  Safety will be assessed by the following: 
• AEs 
• Laboratory test values (hematology, serum chemistry, urinalysis) 
• Electrocardiograms  
• Vital signs  
Study Drug, Dosage, and Route of Administr ation: Open -label study drug (vonoprazan 10 mg or vonoprazan 20 mg) to be 
taken orally QD for 14 days (Day 1 through Day 14). All study drug doses are to be taken preferably prior to eating any breakfast or food with approximately 240 mL (8 oz) water between 7 and 10 am each day.  
Ethical Considerations:  Clinical studies in adults with GERD have shown a positive benefit-risk for vonoprazan. This study is anticipated to provide benefits to children ≥ 6 to < 12 years of age with symptomatic GERD and risks similar to those observed with vonoprazan in adults. This study is needed to identify doses to be used in future trials in children ≥ 6 to < 12 years of age. 
The study was designed to minimize the number of blood samples and 
visits to investigate the pharmacokinetics and safety in this population.  
  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 13 Sample  Size:  Approximately 18 subjects will be enrolled with 9 subjects in each dose 
group. Attempts will be made to enroll subjects across the ≥ 6 to < 12 
years age range. Because this is a pharmacokinetic and safety trial with no 
comparator, there is no power determination affecting the sample size. The sample size of approximately 18 subjects is considered sufficient to assess the pharmacokinetics, safety, and tolerability of vonoprazan in this population. Fewer subjects may be enrolled based on preliminary da ta, if 
considered sufficient to adequately characterize the pharmacokinetic profile.  
Statistical 
Methods:  Pharmacokinetic Endpoints:  
Individual pharmacokinetic parameter estimates will be summarized descriptively by vonoprazan dose.  
Efficacy Endpoint: 
The severity of GERD symptoms at screening and Days 7 and 14, as 
assessed by the investigator, will be summarized overall and by vonoprazan dose. 
Pharmacodynamic Endpoints: 
Mean pH and the percentage of time above pH 4, 5, and 6 at baseline 
(Day -1) and Day 7 will be summarized for the subset of subjects for whom intragastric pH monitoring is available. 
Safety:  
Adverse events will be coded using the Medical Dictionary for 
Regulatory Activities (MedDRA). The number and percentage of subjects 
experiencing treatment -emergent AEs will be summarized by MedDRA 
system organ class and preferred term overall, by severity,  and by 
relationship to study drug for each treatment group.  
Clinical laboratory tests, electrocardiograms, and vital signs will be 
summarized with descriptive statistics at each time point by treatment group. 
Version and 
Date of Protocol:  Amendment 2.0  
30 August 2023 
  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 14 List of Abbreviations  
Abbreviation  Definition  
AE adverse event  
ALT alanine aminotransferase  
AST  aspartate aminotransferase 
AUC ss area under the drug concentration- time curve at steady state  
AUC  τ area under the drug concentration-time curve during the dosing interval 
τ 
CFR  Code of Federal Regulations  
CL/F  Oral clearance  
Cmax,ss maximum drug concentration at steady state 
CYP  cytochrome P450 
ECG  electrocardiogram  
eCRF  electronic case report form  
EE erosive esophagitis 
FDA Food and Drug Administration 
GCP  Good Clinical Practice  
GERD gastroesophageal reflux disease 
GGT  gamma -glutamyl transferase  
H+, K+ -ATPase  hydrogen, potassium–adenosine triphosphatase 
H2RA histamine -2 receptor antagonist 
HBsAg  hepatitis B surface antigen  
hCG human chorionic gonadotropin 
HCV  hepatitis C virus  
HIV human immunodeficiency virus  
ICF informed consent form 
ICH International Council for Harmonisation 
IEC Independent Ethics Committee 
INR international normalized ratio  
IRB Institutional Review Board  
IRT interactive response technology 
LAR  legally authorized representative  
LFT liver function test 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 15 Abbreviation  Definition  
LLC  Limited Liability Company  
MCH  mean corpuscular hemoglobin  
MCV  mean corpuscular volume 
MedDRA  Medical Dictionary for Regulatory Activities  
PCAB  potassium- competitive acid blocker  
popPK population pharmacokinetic 
PPI proton pump inhibitor  
PTE pretreatment adverse event  
QD once daily  
RBC  Red blood cell  
RNA  ribonucleic acid  
SAE  serious adverse event  
sGERD Symptomatic non- erosive gastroesophageal reflux disease  
SoE schedule of events 
SGOT  serum glutamic -oxaloacetic transaminase  
SGPT  serum glutamic -pyruvic transaminase 
SUSAR  suspected unexpected serious adverse reaction  
Takeda  Takeda Pharmaceutical Company Limited  
TEAE treatment -emergent adverse event  
ULN  upper limit of normal 
Vz/F Apparent volume of distribution  
WBC  White blood cell  
Note: Abbreviations used only in tables and figures are defined with the relevant tables and figures.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 16 1 Introduction  
V onoprazan belongs to a new class of acid-inhibitory agents called potassium- competitive 
acid blockers (PCABs). In the United States, vonoprazan in combination with amoxicillin 
and in combination with amoxicillin and clarithromycin have been approved for the treatment of Helicobacter pylori  infection in adults. V onoprazan is being developed for the 
treatment of heartburn in patients with symptomatic non-erosive gastroesophageal reflux disease (sGERD), healing of all grades of erosive esophagitis (EE) and relief of heartburn and maintenance of healing of all grades of EE and relief of heartburn. 
In countries other than the United States, vonoprazan has been studied in other gastric acid-
related diseases such as healing of gas tric and duodenal ulcers, and for the prevention of 
recurrence of gastric or duodenal ulcer during nonsteroidal anti-inflammatory drug or aspirin 
administration. V onoprazan has received regulatory approval for adults in Japan, Russia, and 
other countries in Asia and Latin America for a variety of indications, including the healing 
of erosive esophagitis and maintenance of healing of erosive esophagitis. Vonoprazan is not currently approved for use in pediatric patients in any country.  
Phathom Pharmaceuticals, Inc. licensed the exclusive rights from Takeda Pharmaceutical 
Company Limited (Takeda) to develop, manufacture, and commercialize vonoprazan in the 
United States, Europe, and Canada. 
1.1 Study Rationale  
The purpose of this study is to determine a dose of vonoprazan in children aged ≥ 6 to< 12 
years with symptomatic gastroesophageal reflux disease (GERD) that provides an exposure 
similar to the exposures in adults after administration of vonoprazan 10 or 20 mg once daily (QD). Like proton pump inhibitors, vonoprazan is expected to provide benefit in pediatric patients with GERD.  
1.2 Background  
1.2.1 Epidemiology, Symptoms, and Current Treatments for GERD 
Gastroesophageal reflux disease is prevalent globally and represents one of the most common 
gastrointestinal diseases. Per the Montreal definition, GERD is a condition that develops 
when the reflux of stomach contents causes troublesome symptoms and/or complications 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 17 [Vakil  2006]. The term GERD covers a spectrum of co nditi ons, including symptomatic 
non-erosive GERD, EE, and Barrett’s esophagus. 
The prevalence of GERD increases with age, from 2.5% of children between 3 and 9 years of 
age to 8.5% of those between 10 and 17 years of age [ Nelso
n 2000]. Similarly, the overa ll 
preva
lence of EE increases with age, from 5.5% in infants to 12.4% in children and 
adolescents [ Gilger  2008 ]. Younger children usually present with extraesophageal 
manifestations, regurgitation, and epigastric pain, while older children and adolescents typically present with adult-type GERD symptoms of heartburn and regurgitation [Cezard  2004,  Rosen  2018]. Pediatric GERD is a condition that is not always outgrown and 
can manifest itself as a chronic disease [ Rosen  2018].  
Management of GERD includes lifestyle changes (eg, diet, weight loss, sleeping position), over-the-counter antacids, histamine-2 receptor antagonists (H
2RAs), and proton pump 
inhibitors (PPIs). Proton pump inhibitors are considered superior to H 2RAs for the healing of 
EE and  relief of GERD symptoms and have become the pharmacological mainstay for the 
treatment of adult and pediatric GERD [ Gold  2002, Rosen 2018].  
1.2.2 Vonoprazan  
The gastric hydrogen, potassium–adenosine triphosphatase (H+, K+-ATPase), also known as the proton pump, is responsible for acid secretion from parietal cells in the stomach. It is inactive in the cytosol but relocates from the cytosol to the secretory membrane of the parietal cells when food is present in the stomach, thereby becoming active and pumping 
H+ ions out of the cells and into the canaliculi in exchange for K+ ions. It represents an 
attractive pharmacological target since it is the final step of the acid secretion process.  
Two classes of pharmaceuticals, with distinct mechanisms of action for inhibiting the gastric 
proton pump, have been developed for clinical application: PPIs and PCABs. As a PCAB, 
vonoprazan has a unique mechanism of action and pharmacokinetics relative to PPIs: 
• Acid activation and stability: Conventional PPIs are prodrugs, which are activated by acid and covalently bind to the H+, K+- ATPase; however, activated PPIs are not 
stable in acidic conditions. In contrast, vonoprazan does not require acid activation, is stable in acidic conditions, and has a more durable effect. Further, vonoprazan is 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 18 rapidly protonated in the parietal cell canaliculi, which concentrates the drug 
proximal to the H+, K+- ATPase [ Scarpignato 2019].  
• Activity against proton pumps: V onoprazan inhibits acid secretion by competitively inhi
biting the binding of potassium ions to the H+, K+- ATPase. V onoprazan may 
selectively concentrate in the parietal cells in both the resting and stimulated states 
and binds to the active pumps in a noncovalent and reversible manner. In contrast, 
PPIs covalently bind H+, K+- ATPase o nly when the pump is active, as an acidic 
environment is required for the activation and accumulation of PPIs in the parietal 
cell [ Scott  2015
].  
• V onoprazan maintains acid control over 24 hours with QD dosing [ Enge vik 2020
]. 
V onoprazan can also be dosed in the presence or absence of food, while most PPIs requi
re dosing before a meal to optimize their acid suppressant effect because 
activated pumps are at their highest level post -prandially due to activation of pumps 
by the meal [ Shin 2013].  
• Extended half- life: The mean plasma half -life is typically 7 to 8 hours after single and 
multiple QD administration of vonoprazan 20 mg (TAK- 438_107). This is 
significantly longer than the half- life of conventional PPIs (<2 hours) [ Shin 2013
]. 
• Metabolism: V onoprazan is me ta bolized by a combination of cytochrome P450 
(CYP) isoforms including CYP3A4/5, which does not have a high degree of genetic 
polymorphism as compared with CYP2C19, which is the primary enzyme responsible 
for the metabolism of PPIs [ Shin 2013].  
T
hese unique aspects of the vonoprazan mechanism of action and pharmacokinetics relative 
to PP
Is translate into greater magnitude and duration of gastric acid suppression, which are 
reflected in the pharmacodynamic profile [ Jenkins
 2015; Sakurai  2015].  
The
 pharmacokinetic and pharmacodynamic profiles of vonoprazan were assessed in 
multiple studies, including Study TAK-438_107, which showed rapid rise in pH following vonoprazan administration and a dose response for percent time above pH 4. The mean 
percentage of time above pH 4 on Day 1 for vonoprazan 10 mg, 20 mg, and 40 mg were 
43%, 63%, and 86%, respectively, and by Day 7 were 60%, 85%, and 93%, respectively [Jenkins
 2015].   
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 19 Takeda conducted 8 short- term clinical studies in adults with EE (5  studies) and symptomatic 
non-erosive GERD (3 studies) with treatment durations of 2 to 8 weeks. In addition, Takeda 
conducted 3 studies of maintenance of healing of EE with treatment durations of 24 to 52 weeks. V onoprazan is approved in multiple countries outside of the United S tates for the 
treatment of adults for reflux (erosive) esophagitis (for healing: vonoprazan 20 mg QD up to 
4 weeks or, if insufficient effect, 8 weeks; for maintenance: 10 mg QD or, if insufficient 
effect, 20 mg QD). 
The safety profile of vonoprazan in Phase 3 studies of adults across indications showed no 
evidence of a dose -related increase in adverse effects with vonoprazan from 5  mg to 40 mg 
QD. As of 25 December 2022, the global cumulative post-marketing patient exposure to vonoprazan is estimated to be approximately 97 million patients.  
Overall, with vonoprazan’s pharmacological profile of rapid, potent, and sustained elevations of gastric pH, vonoprazan offers the potential to be a highly effective treatment option for 
children with symptomatic GERD.  
1.3 Justification for Dose  
The proposed pediatric doses are selected to approximate equivalent adult exposures following administration of vonoprazan 10 or 20 mg QD in pediatric patients ≥ 6 to < 12 
years of age.  
The proposed doses are based on simulations using an updated population pharmacokinetic (popPK
) model [ Faci
us 2023]. The 2-compartment linear popPK model for vonoprazan was 
devel
oped with adult pharmacokinetic data from healthy subjects aged 18 to 54 years who 
participated in 9  studies specifically se lected to enable the extrapolation and characterization 
of the disposition of vonoprazan in pediatric subjects. The final dataset consisted of 354 subjects (205 Asian and 149 Western) with 8010 plasma concentration observations. 
 
As planned, an analysis of interim PK data from the first adolescent subjects aged 12 to 17 years randomized in Study VPED-102 was performed using the updated popPK model. Interim data from VPED -102 was combined with adult data from the updated popPK model 
to investigate potential differences in the pharmacokinetic properties of vonoprazan between adolescents and adults. Individual predicted area under the drug concentration- time curve at 
steady state ( AUC
ss) values for the 8 adolescent subjects with symptomatic GERD included 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 20 in the preliminary analysis were within the range expected from healthy adults at their 
respective doses and no obvious effect of age or body weight was observed. Model 
assessments indica ted the updated popPK model was working well in adolescents and 
substantiated the usefulness of simulations using the model to select doses for younger pediatric subjects.   
For predicting the appropriate doses in pediatric subjects aged ≥  6 to <12 years, simulations 
were performed using the updated popPK model for vonoprazan and were summarized by both age and body weight. For reference, all boys and girls aged ≥ 6 to < 12 years who have a body weight between the 5th and 95th percentiles would have a body weight between 15 and 
65 kg. Different model assumptions in terms of the allometric weight scaling exponent (as 
estimated  (none) in the adult data or fixed at 0.2) were compared. 
The updated model was used to simulate posterior distributions of AUC
ss in both adults and 
pediatric subjects aged ≥6 to <12 years or with a body weight of 15 to 65 kg for a series of 
pediatric candidate doses. Matching pediatric doses were selected to limit the predicted 
percentage of pediatric subjects with an exposure exceeding the adult reference exposure (median AUC
ss) at 50%.  
For children aged ≥ 6 to < 12 years  or with a body weight of 15 to 65 kg each of the 
simulations gave similar exposure predictions, thereby suggesting that the selected doses for these pediatric patients (10 and 20 mg) should result in a majority of exposures that are within the 95% prediction interval in adults for both the 10 and 20 mg targeted doses. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 21 2 Study Objectives and Endpoints  
Study objectives with corresponding endpoints are presented in Table  2-1. 
Table 2-1 Study Objectives and Endpoints  
Objectives  Endpoints  
Primary  
• To evaluate the pharmacokinetic profile of 
vonoprazan (10 or 20 mg QD) in children ≥ 6 to 
< 12 years of age who have symptomatic 
GERD.  • Cmax,ss, AUC τ, CL/F, V z/F from data collected on 
Days 7 and 14.  
Safety  
• To evaluate the safety of vonoprazan (10 or 20 
mg QD) in children ≥ 6 to < 12 years of age 
who have symptomatic GERD.  • Adverse events  
• Laboratory test values (hematology, serum chemistry, urinalysis*)  
• Electrocardiograms (ECGs)  
• Vital signs  
Exploratory  
• To evaluate symptom relief and 
pharmacodynamics of vonoprazan (10 or 20 mg) in children ≥ 6 to < 12 years of age who have symptomatic GERD. • The severity of GERD symptoms at baseline and 
Days 7 and 14, as assessed by the investigator  
• Mean pH and % time above pH 4, 5, and 6 at baseline and Day 7 in the subset of subjects for whom intragastric pH monitoring is performed 
when clinically indicated per the investigator.  
AUC τ: area under the drug concentration- time curve during the dosing interval τ; CL/F: oral clearance; C max,ss: 
maximum drug concentration at steady- state; ECGs; electrocardiograms; GERD: gastroesophageal reflux 
disease; QD: once dai ly; V z/F: apparent volume of distribution  
* Urinalysis is only required if deemed necessary by the investigator.  
 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 22 3 Investigational Plan  
3.1 Study Design  
This is a Phase 1, randomized, open- label, parallel -group, multiple-dose study in children 
aged ≥ 6 to < 12 years who have symptomatic GERD. A total of approximately 18 subjects 
will be enrolled.  
Blood samples for pharmacokinetic testing will be collected on Days 7 and 14. Select sites 
will perform gastric pH monitoring in subjects deemed clinically indicated b y the principal 
investigator. Gastric pH will be monitored for 24 hours beginning on Day -1 and on Day 7. 
Following completion of study drug dosing on Day 14 or early discontinuation, the subject 
will be transitioned to local standard of care for 14 days during the Follow-up Period. Note, standard of care does not include the use of study drug but can include other acid suppressant agents.  
A schematic diagram of the overall study design is presented in Figure 3-1. 
 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 24 The study will include 3 periods ( see the schedule of events [SoE] in Section  13.1 for 
details ). 
Screening Period (≤ 4 weeks):  Subjects will undergo screening assessments to determine 
study eligibility, and baseline assessments wi ll be performed. If all eligibility criteria are met, 
the subject will be randomized and enter the Treatment Period. 
Treatment Period (Day 1 to Day 14): Subjects will be randomized to receive 1 of 
2 vonoprazan doses (10 mg QD or 20 mg QD) for 14 days. 
Follow-up Period (2 weeks): A safety follow-up visit phone call will occur 2 weeks after the 
last dose of study drug to assess adverse events (AEs). Following completion of study drug 
dosing or early discontinuation, the subject will be transitioned to local s tandard of care for 
14 days. 
End-of-study definition:  A subject will be considered to have completed the study (up to 8 
weeks, including 4 weeks of screening, 2 weeks of treatment and 2 weeks of safety follow-
up) if the subject completes the Treatment Peri od and the safety follow-up visit phone call. 
3.1.1 Rationale of Study Design  
Blinding is not necessary in this study since the primary objective is to evaluate the pharmacokinetic profile of vonoprazan. The pharmacokinetic endpoints are objective and 
unlikely to be biased by the open-label design.  
A parallel -group design with 2 dose levels of vonoprazan (10 and 20 mg QD) was selected to 
provide unbiased estimates of the vonoprazan pharmacokinetic and safety profile across 
doses likely to be safe and efficacious  in children aged ≥ 6 to < 12 years. Dose justification is 
provided in Section  1.3. A placebo control group is not considered practical or ethical in 
children aged ≥ 6 to < 12 years with symptoms of GERD. 
Pharmacokinetic studies with PPIs (dexlansoprazole, esomeprazole, lansoprazole, 
rabep
razole) in pediatric GERD patients were generally less than 7 days [ Gunas
ekaran  2002, 
Gremse 2002, James  2007, K ukulka 2014, Kukulka 2012, Li  2006, Rosen  2018, 
Zannikos 2011, Zhao  2006]. Historical PPI data (esomeprazole, lansoprazole, pantoprazole) 
in pediatric GERD patients have shown benefit in terms of resolution of heartburn and other GERD symptoms within a week of treatment [ Gold  2007, Gunasekaran  2002, Tolia  2006].  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 25 The pharmacological profile of vonoprazan relative to PPIs suggest that, if effective, the 
onset of efficacy in pediatric patients would be similar or earlier than with PPIs.  
This study will include children aged ≥ 6 to < 12 years who have symptomatic GERD with or 
without EE. In Study EE-301, which enrolled 1027 adult subjects with endoscopically confirmed EE of Los Angeles Classification Grades A to D, 514 subjects were evaluated for 
EE heali ng after receiving vonoprazan 20 mg QD for 2 weeks. Of the 514 subjects, 74.3% 
had healed EE at Week 2. Based on this data, the proposed 14- day treatment duration will 
provide clinical benefit to subjects with EE, with a possibility of healing of EE. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 26 4 Subje ct Selection and Withdrawal Criteria  
4.1 Selection of Study Population  
This study will be conducted at approximately 20 to 25 sites in the United States and Europe. 
Approximately 18 subjects will be enrolled. 
4.1.1 Inclusion Criteria  
Subjects are eligible for enrollment in the study if they meet all of the following inclusion criteria:  
1. The subject is ≥ 6 to < 12 years of age at the time of informed consent signing. 
2. The subject has a body weight within the 5
th through 95th percentile by age, inclusive, 
as determined b y the National Center for Health Statistics (Section  13.6). 
3. The subject must have a diagnosis of GERD prior to randomization and medical history of signs or symptoms of GERD for at least 3 months prior to screening, based 
on physical examination, current symptoms (eg, heartburn), or diagnostic tests (eg, 
pH or endoscopy). Notes in the medical records and/or other source documents, such as prior endoscopies, can be used to support the diagnosis and will be recorded in the electronic case report form ( eCRF).  
4. The subject has at least one moderate GERD symptom based on the GERD Symptom Assessment -Investigator scale performed at screening.  
5. The subject must be able to swallow study drug tablet with water. 
6. Parent or legal guardian (ie, legally authorized rep resentative [LAR]) is willing and 
able to complete the informed consent process and subjects are able to comply with study procedures and visit schedule. 
7. Female subjects who have experienced menarche must have a negative pregnancy test 
and w
ill be counseled on pregnancy avoidance (Section 13.2).    
 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 27 4.1.2 Exclusion Criteria 
Subjects are not eligible for study participation if they meet any of the following exclusion 
criteria:  
1. The subject has used prescription or non-prescription PPIs or H 2RAs within 7 days 
prior to randomization or requires use during the Treatment Period.  
2. The subject has used sucralfate, or antacids within 1 day prior to randomization or requires their use during the Treatment Period.  
3. The subject has received other agent s affecting digestive organs, including muscarinic 
antagonists (eg, hyoscyamine), prokinetics, oral anticholinergic agents, 
prostaglandins, bismuth from 30 days prior to Day 1 or requires their use during the 
course of the study. 
4. The subject has received atazanavir sulfate or rilpiv irine hydrochloride from 5 days 
prior to Day 1 or requires their use during the course of the study.  
5. The subject has received any investigational compound (including vonoprazan) within 30 days prior to the start of the Screening  Period. 
6. The subject is an immediate family member or is in a dependent relationship with a 
study site employee who is involved in the conduct of this study (eg, child, sibling) or 
subject may have consented under duress. 
7. The subject requires hospitalizati on or has surgery scheduled during the course of the 
study or has undergone major surgical procedures within 30 days prior to the 
Screening Period. 
8. The subject has undergone prior gastrointestinal surgeries. 
9. The subject has any abnormal laboratory test val ues that are considered clinically 
significant in the opinion of the investigator during the Screening Period. 
10. The subject has a history of hypersensitivity or allergies to vonoprazan (including the 
formulation excipients:  D-mannitol, microcrystalline cellulose, hydroxypropyl 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 28 cellulose, fumaric acid, ascorbic acid, croscarmellose sodium, magnesium stearate, 
hypro mellose, macrogol 8000, and titanium dioxide, or red or yellow ferric oxide). 
11. The subject has used any prescription or over-the-counter medications (including 
her
bal or nutritional supplements), other than those already excluded in criteria 1 to 5 
above, within 14 days before the first dose of study drug or throughout the study. That 
is, unless the medication(s) is permitted by the sponsor following a review of 
available data which confirms concomitant administration of the medication is 
unlikely to affect either the safety of the patient or the pharmacokinetics of vonoprazan. 
12. The subject has consumed grapefruit or grapefruit juice, Seville orange or Seville ora
nge-containing products (eg, marmalade), or other food products that may be 
CYP3A4 inhibitors (eg, vegetables from the mustard green family [kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard] and charbroiled 
meats) within 7 days (or 5 half-lives) before the first dose of study drug or throughout 
the study. 
13. The subject has positive results at screening for human immunodeficiency virus, 
hepatitis B virus, or hepatitis C virus (HCV) infection at screening. 
14. The subject h as severe renal impairment (estimated glomerular filtration rate < 30 
mL/min).  
15. The subject has moderate to severe hepatic impairment (Child -Pugh Class B and 
Child -Pugh Class C). 
16. The subject has any of the following abnormal laboratory test values at the st art of the 
Screening Period: 
a. Creatinine levels: > 1 mg/dL (>88 μ mol/L).  
b. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2  × the 
upper limit of normal (ULN) or total bilirubin >2 × ULN (except subjects with 
Gilbert Syndrome). 
17. In the opinion of the investigator, the subject is not suitable for entry into the study. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 29 4.1.3 Screen Failures 
Screen failures are defined as subjects whose LAR signed the informed consent form (ICF) 
to participate in the clinical study but are not subsequently entered in the Treatment Period of the study. A minimal set of screen failure information is required to ensure transparent reporting of screen failure subjects to meet the Consolidated Standards of Reporting Trials 
publishing requirements and to respond to quer ies from regulatory authorities. Minimal 
information includes demography, screen failure details, eligibility criteria, pretreatment 
adverse events (PTEs), AEs, and any serious adverse events (SAEs). 
Subjects may be allowed to be rescreened upon discussion with and approval by the medical 
monitor.  
4.2 Withdrawal of Subjects From Study Drug and/or the Study  
The duration of the study is defined for each subject as the date signed written informed consent is provided through the last follow-up visit phone call performed 2  weeks after 
completing the last dose of study drug in the Treatment Period. 
4.2.1 Reasons for Withdrawal/Discontinuation  
Subjects or LARs may withdraw from the study at any time (eg, Treatment Period, Follow-up Period) and for any reason without prejudice to their future medical care by the investigator 
or at the study site. Every effort should be made to keep subjects in the study. The primary reason for discontinuation or withdrawal of the subject from the study drug or the study should be recorded in the eCRF. For screen failure subjects, refer to Section 4.1.3.  
A subject may be withdrawn from the study for any of the following reasons: 
1. Adverse event or SAE: The subject has experienced a PTE, AE, or SAE that requires 
early termination because continued participation imposes an unacceptable risk to the 
subject’s health, or the subject is unwilling to continue because of the PTE, AE, or 
SAE. 
Note: If a subject is discontinued from study participation due to a PTE, AE, or SAE, the event will be followed until it is fully resolved or stable.  
2. Liver function test (LFT) abnormalities: Appropriate clinical follow -up (including 
repeat laboratory t ests) is to be done until a subject’s laboratory profile has returned to 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 30 normal/baseline status. See Section  13.2 to monitor LFT abnormalities and f or the 
criteria of liver function abnormalities for temporary and permanent discontinuation 
of study drug. 
3. Significant protocol deviation: The discovery post-randomization that the subject failed to meet protocol entry criteria or did not adhere to protocol requirements, and 
continued participation poses an unacceptable risk to the subject’s health. 
4. Lost to follow-up: The subject did not return to the clinic and attempts to contact the 
subject were unsuccessful. Attempts to contact the subject must be documented (3 documented telephone contact attempts and 1 certified letter, at a minimum) within 
6 weeks of the most recent planned visit. 
5. V oluntary withdrawal: The subject or the LAR wishes to withdraw from the study. The reason for the withdrawal, if provided, should be recorded in the eCRF. Note: All attempts should be made to determine the underlying reason for the 
withdrawal and, where possible, the primary underlying reason should be recorded 
(ie, withdrawal due to an AE or lack of efficacy). 
6. Study termina tion: The sponsor, Institutional Review Board ( IRB)/Independent Ethics 
Committee s (IECs ), or regulatory agency terminates the study. 
7. Pregnancy: The subject is found to be pregnant. Note: If the subject is found to be pregnant, the subject must be withdrawn immediately from the treatment. See Section  6.3.2 for further instructions on pregnancy. 
8. Lack of efficacy: The investigator has determined that the subject is not benefiting from investigational treatment and continued participation would pose an unacceptable risk to the subject. 
9. Other: The subject is discontinued from the study for any reason other than those 
listed above. The specific reason(s) for subject discontinuation will be recorded in the 
eCRF where appropriate.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 31 4.2.2 Handling of Withdrawals  
Subjects or LARs are free to withdraw from the study drug or the study at any time upon 
request.  
Subject participation in the study may be stopped at any t ime at the discretion of the 
investigator. 
Following completion of study drug dosing or early discontinuation, the subject will be 
transitioned to local standard of care in accordance with each site’s prespecified process.  
Subjects who discontinue study drug or active participation in the study will no longer receive study drug. When a subject withdraws from the study drug or active participation in 
the study, the reason(s) for withdrawal shall be recorded by the investigator on the relevant 
page of the eCR F. Whenever possible, all subjects who discontinue study drug or withdraw 
from the study prematurely will undergo all end-of-study assessments. Subjects who fail to 
return for final assessments will be contacted by the site to make every attempt to comply 
with the protocol. 
It is vital to obtain follow -up data on any subject withdrawn because of an AE or SAE. In 
every case, efforts must be made to undertake protocol- specified follow -up procedures to 
assess safety.  
See the SoE in Section  13.1 for data to be collected at the time of discontinuation of study 
drug and follow-up and for any further evaluations that need to be completed. The investigator may discontinue a subject’s study participation at any time during the study 
when the subject meets the study termination criteria described in Section 4.2.1. 
4.2.3 Lost to Follow -up 
A subject will be considered lost to follow-up if the LAR signed the ICF, the subject fails to 
return for scheduled visits during the Treatment Period or Follow-up Period, and the LAR is 
unable to be contacted by the study site. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 32 The following actions must be taken if a subject fails to return to the clinic for a required 
study visit: 
• The site must attempt to contact the LAR and reschedule the missed visit as soon as possible, counsel the subject and LAR on the importance of maintaining the assigned 
visit schedule and ascertain whether or not the subject and LAR wish to and/or should continue in the study. 
• Before a subject is deemed lost to follow-up, the investigator or designee must make 
every effort to regain contact with the LAR (wh ere possible, 3 telephone calls and, if 
necessary, a certified letter [or local equivalent methods] to the subject’s last known 
mailing address within 6 weeks of most recent planned visit). These contact attempts 
should be documented in the subject’s source document. 
• Should the LAR continue to be unreachable, the subject will be considered to have withdrawn from the study due to being lost to follow-up. 
4.2.4 Replacements  
At the discretion of the sponsor, subjects may be replaced to achieve the target of 
approximately 18 subjects with expected usable pharmacokinetic sample collections.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 33 5 Study Drugs  
5.1 Method of Assigning Subjects to Treatment Groups  
Subjects who meet all of the inclusion criteria and none of the exclusion criteria will be 
randomized in a 1:1 ratio to 1 of the following 2 groups during the Treatment Period: 
• V onoprazan 10 mg QD for 14 days 
• V onoprazan 20 mg QD for 14 days 
An interactive response technology (IRT) system will be used to administer the randomization schedule. Biostatistics will generate the  randomization schedule using SAS 
software Version 9.4 or later (SAS Institute Inc, Cary, North Carolina) for IRT, which will link sequential subject randomization numbers to treatment codes. The randomization will 
also use an appropriate block size, which will not be revealed. 
5.2 Treatments Administered  
Subjects will be administered study drug orally at the clinic on Day 1 and on Days 7 and 14, after the pre-dose pharmacokinetic sample, with approximately 240 mL (8 oz) of water in the 
morning between 7 and 10 am preferably prior to eating any breakfast or food. If necessary, a dosing cup can be used to facilitate administration. Study drug will be dispensed to the 
parent/LAR for study drug to be administered to the subject at home. Clinic staff will provide 
the parent/LAR a Study Drug Reminder Card and instruct the parent/LAR to record the date 
and time of every dose taken at home and to bring this card back to the next clinic visit.  
On Days 2 to 6 and 8 to 13, the parent/LAR will be instructed to give the subject study drug 
orally with approximately 240 mL (8 oz) of water each morning between 7 and 10 am 
preferably prior to eating any breakfast or food. Any missed doses should also be recorded by 
the parent/LAR and communicated to clinic staff immediately. All dosing information 
including missed doses will be recorded on the Study Drug Reminder Card and in the eCRF. 
On Days 7 and 14 subjects may have a meal/snack 30 to 60 minutes after study drug dosing. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 34 Following completion of study drug dosing on Day 14 or early discontinuation, the subject 
will be transitioned to local standard of care for 14 days. Note, the local standard of care does 
not include study drug but can include other acid suppressant agents.  
5.3 Identity of Investigational Product  
V onoprazan study medication will be supplied as 10 mg and 20 mg tablets.  
 manufactures the vonoprazan fumarate drug 
substance.  manufactures the 
vonoprazan tablets. 
V onoprazan tablets contain vonoprazan free base (MW 345.39) and the following inactive 
excipients: D -Mannitol, microcrystalline cellulose, hydroxypropyl cellulose, fumaric acid, 
ascorbic acid, croscarmellose sodium, magnesium stearate, hypromellose, polyethylene 
glycol 8000, titanium dioxide, and red or yellow ferric oxide. 
Study drug will be packaged for shipment to the investigational site. 
5.4 Management of Clinical Supplies 
5.4.1 Study Drug Packaging and Storage  
V onoprazan tablets will be packaged and shipped by . Study supplies must be stored in a secure area (eg, a locked cabinet), protected from 
moisture, and kept at a controlled room temperature (20°C to 25°C [68°F to 77°F]; excursions are allowed between 15°C and 30°C [59°F to 86°F]) until they are used or returned to the sponsor or designee for destruction. Study drug must be stored under the 
conditions specified on the label and remain in the original container until dispensed. 
Sites should refer to the pharmacy manual for detailed information regarding packaging and 
labeling and for reporting temperature excursions. 
5.4.2 Study Drug Accountability  
The investigator will maintain accurate records of receipt of all study drug, including dates of receipt. In addition, accurate records will be kept regarding when and how much study drug is dispensed and used by each subject in the study. Reasons for departure from the expected 

Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 35 dispensing regimen must also be recorded. At the completion of the study, to satisfy 
regulatory requirements regarding drug accountability, all study drug will be reconciled and 
retained or destroyed according to applicable regulations. 
Sites should refer to the pharmacy manual and follow the accountability process described 
for this clinical study.  
5.5 Overdose Management  
An overdose is defined as a known deliberate or accidental administration of investigational drug, to or by a study subject, at a dose above that which is assigned to that individual subject according to the study protocol. 
Cases of overdose without manifested signs or symptoms are not considered AEs. Adverse 
events associated with an overdose will be documented on the AE eCRF(s) according to Section  6.3.1.3.1. The SAEs associated with overdose should be reported according to the 
procedure outlined in Section 6.3.1.3.2. 
5.5.1 Treatment of Overdose  
V onoprazan is not removed from circulation by hemodialysis. In the event of drug overdose, the subject should be treated symptomatically.  
5.6 Blinding  
This is an open- label study.  
5.7 Study Compliance  
5.7.1 Treatment Compliance  
Compliance with study drug is to be assessed as specified in the SoE (Section 13.1). Compliance with study drug dosing will be assessed by clinic staff reviewing the Study Drug Reminder Card returned at each visit, direct questio ning and counting any returned tablets, 
which will be documented in the source documents and eCRF.  
The date and time of each dose taken (in clinic or at home) must be recorded on the Study 
Drug Reminder Card, source documents and eCRF. If a subject misses any dose for any 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 36 reason, the sponsor must be notified immediately, and the date of the missed dose(s) and 
reason must be recorded in the eCRF.   
If a subject misses a scheduled visit or exhibits poor compliance, as assessed by tablet 
counts, the sponsor s hould be notified immediately to determine appropriate mitigation. 
Actions may include subjects provided with specific dosing instructions to continue study 
drug or discontinuation from the study. The LARs and subjects should be counseled at each 
visit on the importance of good compliance regarding the dosing regimen and scheduled study visits.    
5.8 Prior and Concomitant Therapy  
Any medication including H 2RAs and PPIs or vaccines (including over-the-counter or 
prescription medicines, vitamins, and/or herbal supplements) that the subject is receiving at the time of screening (or has received within 30 days before the time of screening) or 
receives during the study must be recorded along with the following: 
• Reason for use 
• Dates of administration, including start and end dates 
• Dosage information, including dose and frequency 
The LARs and subjects are to be instructed that the subject should not take any medications, 
including over-the-counter medications, without first consulting the investigator or 
subinvestigators. However, single-use medications for endoscopic examination and topical 
medications, including liniments, ophthalmic drops, nasal drops, ear drops, inhaled drugs, adhesive skin patches, and gargle (mouthwash) will be allowed, whether or not they are excluded or restricted.  
The medical monitor should be contacted if there are any questions regarding prior or concomitant therapy. 
  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 37 5.8.1 Excluded Medications  
A list of excluded medications is provided in Table  5-1. 
Table 5-1 Excluded Medications and Treatments  
Excluded Medications and Treatments  Beginning of 
Exclusion End of Exclusion  
Other investigational drugs or drugs administered due 
to participation in another clinical trial  30 days prior to start of Screening Period Follow-up  phone call 
Antacids and sucralfate  Day -1 (day before first 
dose of study drug) Day 14 (end of 
study drug 
dosing) 
H2RAs 7 days prior to Day 1 Day 14 (end of 
study drug 
dosing) 
PPIs 7 days prior to Day 1 Day 14 (end of 
study drug dosing) 
Strong inhibitors or inducers of CYP3A4 
(eg, itraconazole, ketoconazole, indinavir, nelfinavir, 
ritonavir, saquinavir, telithromycin)  14 days prior to Day 1  Day 14 (end of study drug 
dosing) 
CYP3A4 substrates with a narrow therapeutic index  14 days prior to Day 1  Day 14 (end of 
study drug dosing) 
CYP2C19 substrates clopidogrel, citalopram, 
cilostazol  14 days prior to Day 1  Day 14 (end of 
study drug 
dosing) 
Other agents affecting digestive organs, including 
muscarinic antagonists (eg, hyoscyamine), prokineti cs, oral anticholinergic agents, 
prostaglandins, bismuth  30 days prior to Day 1  Follow-up  
phone call 
Atazanavir sulfates; rilpivirine hydrochloride 
(contraindicated with vonoprazan) 5 days prior to Day 1  Follow -up  
phone call 
CYP: cytochrome P450 isoenzyme; H 2RA: histamine -2 receptor antagonist; PPI: proton pump inhibitor  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 38 6 Study Assessments and Procedures  
Prior to undergoing any protocol- specific procedures or assessments, all LARs of potential 
subjects must sign and date the ICF. Participating subjects will provide assent as applicable. 
Subjects and LARs will have the opportunity to have any questions answered before signing the ICF. The investigator must address all questions raised by the subject and LAR. The 
investigator or designee will also sign and date the ICF. 
Study procedures and their timing are summarized in the SoE (Section 13.1). Adherence to 
the study design requirements, including those specified in the SoE, is essential and required for study conduct. All safety concerns should be discussed with the principal investigator and 
medical monitor immediately to determine if any active intervention is needed, including 
action taken with study drug. All screening evaluations must be completed and reviewed to confirm that potential subjects meet all eligibility criteria. The investigator will maintain a 
screening log to record details of all subjects screened and to confirm eligibility or record 
reasons for screening failure, as applicable.  
6.1 Pharmacokinetic and Pharmacodynamic Assessments  
6.1.1 Pharmacokinetic Assessments  
Parents/LARs will ensure that the subject arrives at the clinic in the morning on Days 7 and 14 for pharmacokinetic sampling. Subjects should not eat or take the vonoprazan study drug 
before arriving at the clinic. The Day 7 and 14 dose of study drug will be given in the clinic.   
Blood samples for pharmacokinetic analysis of vonoprazan in plasma will be collected on 
Days 7 and 14. On Day 7, one pre-dose sample will be collected prior to the morning administration of vonoprazan along with two additional samples collected after drug 
administration: one between 0.5 to 1.5 hours post-dose and one between 2.5 to 3.5 hours 
post-dose. On Day 14, one pre-dose sample will be collected prior to the morning administration of vonoprazan along with two additional samples collected after drug administration: one between 1 to 2 hours post-dose and one between 3 to 4 hours post-dose. 
The exact date and time of each pharmacokinetic sample must be recorded in subject source 
document and eCRF. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 39 If a subject terminates early, an attempt should be made to collect one blood sample if it can 
be collected within 24 hours following the last dose of study drug. The exact date and time of 
the early termination sample must be recorded.  
Blood samples will be collected into sodium heparin vacutainer collection tubes and 
processed into plasma. Details of collection, processing, storage and shipping will be 
contained in the Clinical Laboratory Manual. 
Bioanalytical Methods Plasma concentrations of vonoprazan will be measured at Labcorp Early Development 
Laboratories Inc. (Madison, WI) using a validated liquid chromatrography/mass spectrometry 
method with an analytical range of 0.5 to 100 ng/mL and will be used for the calculation of 
the plasma vonoprazan pharmacokinetic parameters.  
Depending on pace of enrollment, pharmacokinetic samples from a subset or subsets of subjects may be analyzed prior to the completion of enrollment. In any case, all of the 
pharmacokinetic samples collected from a given subject will be analyzed in the same 
bioanalytical batch.  
Pharmacokinetic Parameters  
Plasma pharmacokinetic parameters shown in Table 6 -1 will be estimated using a non -lin
 ear 
mixed effects model and will be determined from the concentration- time data for all 
evaluable subjects. The primary vonoprazan pharmacokinetic endpoints will include the following steady state parameters: C
max,ss, AUC τ, CL/F and V z/F. Actual sampling times,  
rather than scheduled or nominal sampling times, will be used in all computations using sampling time. Additional pharmacokinetic parameters may be estimated as appropriate.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 40 Table 6-1 Pharmacokinetic Parameters to be Estimated using Vonoprazan Plasma 
Concentration Data 
Parameter  Definition  
Cmax,ss Maximum observed plasma concentration at steady state  
Cmax,ss/Dose Dose -normalized C max,ss (Cmax,ss divided by the administered dose in mg)  
AUC τ,ss Area under the plasma concentration -time curve during the dosing interval τ, where τ is 
the length of the dosing interval in hours, calculated using the linear trapezoidal rule 
AUC τ,ss/Dose  Dose -normalized AUC τ,ss (AUC τ,ss divided by the administered dose in mg) 
λz Terminal elimination rate constant, calculated as the negative slope of the log -linear 
regression of the natural logarithm concentration -time curve during the terminal phase  
CL/F  Apparent total plasma clearance after oral (extravascular) administration, calculated as 
Dose/ AUC τ,ss 
Vz/F Apparent volume of distribution during the terminal elimination phase after oral 
(extravascular) administration, calculated as (CL/F)/ λ z 
 
6.1.2 Pharmac odynamic Assessments  
Select sites may participate in a sub -study collecting gastric pH when deemed clinically 
necessary by the principal investigator. In the pharmacodynamic sub-study, gastric pH will be 
measured and recorded continuously for a 24-hour period on Day -1 and Day 7 as outlined in 
the SoE ( Section  13.1) using a suitable pH probe and ambulatory pH recording system . All 
instruments will be calibrated prior to and following use. Gastric pH will be sampled and 
recorded every 5 seconds. The 24-hour continuous pH recording session for Day -1 will commence 24-hours prior to the first  dose of study drug. The 24-hour continuous pH 
recording session for Day 7 will commence 30 to 60 minutes prior to the next dose of study drug. The reason for pH assessments, start time, stop time and any interruptions will be recorded in the source document and the eCRF. To minimize the discomfort of probe insertion, administration of a topical anesthetic (lidocaine) will be permitted per the 
institutional process. Details of collection, processing, storage and shipping will be contained 
in the Gastric pH Monitoring Plan.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 41 6.2 Efficacy Assessments  
6.2.1 GERD Symptom Assessment -Investigator  
The GERD Symptom Assessment-Investigator scale evaluates 4 symptoms of GERD: 
heartburn, vomiting, acid regurgitation, and trouble eating. The maximum severity of each GERD symptom occurring during the 7 days prior to the study visit, Day 7 and Day 14 will 
be assessed. The severity for each symptom will be recorded as either none, mild, moderate, 
severe or very severe. At screening, the subject will be eligible for inclusion in the study if the subject has at least one moderate GERD symptom. Symptom and seve rity definitions are 
presented in Section  13.4.1. 
6.3 Safety Assessments  
6.3.1 Pretreatment Events and Adverse Events  
6.3.1.1  Definitions  
6.3.1.1.1  Definitions of Pretreatment Adverse Events  
A PTE is defined as any untoward medical occurrence in a clinical investigation subject whose informed consent to participate in a study has been signed, which has occurred prior to 
administration of any study drug; it does not necessarily have to have a causal relationship 
with study participation. 
6.3.1.1.2  Definitions of Adverse Events  
An AE is defined as any untoward medical occurrence in a subject enrolled into this study 
regardless of its causal relationship to study drug. An AE can therefore be an unfavorable 
sign or symptom, or a disease temporally associated with the use of study drug. 
A treatment -emergent adverse event (TEAE) is defined as any event that occurs after the first 
dose of study drug or any event at baseline that worsens in either intensity or frequency after 
the first dose of study drug. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 42 6.3.1.1.3  Serious Adverse Events  
An SAE is defined as any untoward medical occurrence at any dose for which the following 
occurs:   
1. Results in DEATH.  
2. Is LIFE -THREATENING. The term “life -threatening” refers to an event in which the 
subject was at risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe.  
3. Requires inpatient HOSPITALIZATION or prolongation of existing hospitalization.  
4. Results in persistent or significant DISABILITY/INCAPACITY .  
5. Is a CONGENITAL ANOMALY/BIRTH DEFECT.  
6. Is an IMPORTANT MEDICAL EVENT that satisfies any of the following:  
• May require intervention to prevent items 1 through 5 above 
• May i nclude any event or symptoms described in the medically significant AE list 
(Table  6-2) 
• Exposes the subject to danger, even though the event is not immedi ately 
life-threatening or fatal or does not result in hospitalization 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 43 Table 6-2 Medically Significant Adverse Event List  
Term  
Acute respiratory failure / acute respiratory distress syndrome  
Torsade de pointes / ventricular fibrillation / ventricular tachycardia 
Malignant hypertension Convulsive seizure 
 
Agranulocytosis  Aplastic anemia  
Toxic epidermal necrolysis/Stevens -Johnson syndrome  
Hepatic necrosis  
Acute liver failure  
Anaphylactic shock  
Acute renal failure  
Pulmonary hypertension Pulmonary fibrosis Confirmed or suspected endotoxin shock Confirmed or suspected transmission of infectious agent by a medicinal product Neuroleptic malignant syndrome / malignant hyperthermia Spontaneous abortion / stillbirth and fetal death 
 
The PTEs that fulfill one or more of the serious criteria above are also to be considered SAEs 
and should be reported and followed up in the same manner (see Section 6.3.1.3.2 and 
Section  6.3.1.3.3).  
If a subject is noted to ALT or AST value >3 × the UL N and a total bilirubin value 
>2 × ULN, for which an alternative etiology has not been identified, the event should be 
recorded as an SAE and reported as per Section  6.3.1.3.2. The investigator must contact the 
medical monitor for discussion of the relevant subject details and possible alternative etiologies, such as acute viral hepatitis A or B or other acute liver disease or medical history or concurrent medical conditions. Follow-up laboratory tests, as described in Section 6.3.3, must also be performed. In addition, if the LFT increases are SAEs, a Liver Function Test 
Increase Form must be completed and transmitted (see  Section  13.2).  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 44 6.3.1.1.4  Adverse Events of Specia l Interest  
An AE of special interest is a noteworthy event for the particular product or class of products 
that a sponsor may wish to monitor carefully. It could be serious or nonserious (eg, hair loss, loss of taste, impotence), and could include events that might be potential precursors or prodromes for more serious medical conditions in susceptible individuals. 
Adverse events of special interest include any event listed in Table  6-3. 
Table 6-3 Adverse Events of Special Interest List  
Term  
Hepatotoxicity  
Severe cutaneous adverse reactions, including hypersensitivity 
Clostridium difficile  infections and pseudomembranous colitis 
Hypersensitivity reactions (anaphylaxis)  Acute interstitial nephritis/tubulointerstitial nephritis   
Bone fracture 
Hematologic abnormalities  
 
For additional details on liver function monitoring, see Section 13.2. 
6.3.1.1.5  Additional Points to Consider for PTEs and AEs  
An untoward finding generally may involve the following: 
• Indicates a new diagnosis or unexpected worsening of a pre-existing condition. 
(Intermittent events for pre -existing conditions or underlying disease should not be 
considered PTEs or AEs.) 
• Necessitates therapeutic intervention. 
• Requires an invasive diagnostic procedure. 
• Requires discontinuation or a change in dose of study drug or a concomitant medication.  
• Is considered unfavorable by the investigator for any reason.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 45 • Is caused by a study procedure (eg, a bruise after blood collection); these events 
should be recorded as a PTE/AE. 
Diagnoses versus signs and symptoms: 
• Each event is required to be recorded to represent a single diagnosis or disorder using standard medical terminology rather than individual symptoms. Accompanying signs 
(including abnormal laboratory values or ECG findings) or symptoms should NOT be 
record ed as additional AEs. If a diagnosis is unknown, sign(s) or symptom(s) should 
be recorded appropriately as a PTE(s) or as an AE(s).  
Laboratory values and ECG findings: 
• Changes in laboratory values or ECG parameters are only considered to be PTEs or AEs if  they are judged to be clinically significant (eg, if some action or intervention is 
required or if the investigator judges the change to be beyond the range of normal 
physiologic fluctuation). A laboratory retest and/or continued monitoring of an abnormal value are not considered an intervention. In addition, repeated or additional noninvasive testing for verification, evaluation, or monitoring of an abnormality is 
not considered an intervention. 
• If abnormal laboratory values or ECG findings are the result of a pathology for which there is an overall diagnosis (eg, increased creatinine in renal failure), the diagnosis 
only should be reported as a PTE or as an AE. 
Pre-existing conditions: 
• Pre-existing conditions (present at the time of signing informed conse nt) are 
considered concurrent medical conditions and should NOT be recorded as PTEs or AEs. Abnormal findings identified at baseline evaluations and screening assessments (eg, laboratory tests, ECG, endoscopy, or X-rays) should NOT be recorded as PTEs 
unless related to study procedures. However, if the subject experiences a worsening 
or complication of a concurrent condition, the worsening or complication should be recorded appropriately as a PTE (worsening or complication occurs before start of 
study drug) or an AE (worsening or complication occurs after start of study drug). 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 46 Investigators should ensure that the event term recorded captures the change in the 
condition (eg, “worsening of…”).  
• If a subject has a pre-existing episodic condition (eg, asthma, epilepsy), any occurrence of an episode should only be captured as a PTE/AE if the episodes 
become more frequent, serious, or severe in nature, that is, investigators should ensure that the AE term recorded captures the change in the condition from baseline 
(eg “worsening of…”).  
• If a subject has a degenerative concurrent condition (eg, cataracts, rheumatoid arthritis), worsening of the condition should only be captured as a PTE/AE if 
occurring to a greater extent than that which would be expected. Again, inve stigators 
should ensure that the AE term recorded captures the change in the condition (eg, “worsening of…”).  
Worsening of PTEs or AEs: 
• If the subject experiences a worsening or complication of a PTE after starting 
administration of the study drug, the worsening or complication should be recorded appropriately as an AE. Investigators should ensure that the AE term recorded 
captures the change in the condition (eg, “worsening of…”).  
• If the subject experiences a worsening or complication of an AE after any change in 
study drug, the worsening or complication should be recorded as a new AE. Investigators should ensure that the AE term recorded captures the change in the 
condition (eg, “worsening of…”).  
• At each required study visit, all AEs that have occurred since the previous visit or 
AEs that have changed in severity since the previous visit must be recorded in the AE 
record of the eCRF.  
Changes in severity of AEs/serious PTEs: 
• If the subject experiences a change in severity of an AE/serious PTE, the event sho uld 
be captured once with the maximum severity recorded. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 47 Preplanned procedures:  
• Preplanned procedures that were scheduled prior to signing of informed consent are 
not considered PTEs or AEs. However, if a preplanned procedure is performed early 
(eg, as an  emergency) due to a worsening of the pre-existing condition, the worsening 
of the condition should be captured appropriately as a PTE or an AE. Complications resulting from any planned procedure should be reported as AEs. 
Elective surgeries or procedures:  
• Elective procedures performed where there is no change in the subject’s medical 
condition should not be recorded as PTEs or AEs but should be documented in the 
subject’s source documents. Complications resulting from an elective surgery should 
be reporte d as AEs.  
Insufficient clinical response (lack of efficacy):  
• Insufficient clinical response, efficacy, or pharmacologic action should NOT be recorded as an AE. The investigator must make the distinction between exacerbation 
of pre -existing illness and lack  of therapeutic efficacy.  
Overdose: 
• Any manifested side effects will be considered AEs and will be recorded on the AE 
page of the eCRF.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 48 6.3.1.2  Documenting Adverse Events 
6.3.1.2.1  Assessment of Severity  
The severity or intensity of an AE refers to the extent to which an AE affects the subject’s 
daily activities. The intensity of the AE will be rated as mild, moderate, or severe using the 
following criteria:  
Mild:  The event is transient and easily tolerated by the subject.  
Moderate:  The event causes the subject discomfort and interrupts the subject’s usual 
activities.  
Severe:  The event causes considerable interference with the subject’s usual activities.  
 
Changes in the severity of an AE should be documented to allow an assessment of the 
duration of the event at each level of intensity to be performed. Adverse events characterized 
as intermittent do not require documentation of onset and duration of each episode. 
6.3.1.2.2  Assessment of Causality  
The investigator’s assessment of an AE’s relationship to study drug is part of the 
documentation process, but it is not a factor in determining what is or is not reported in the 
study. If there is any doubt as to whether a clinical observation is an AE, the event should be 
reported. 
The relationship or association of each AE to study drug(s ) will be assessed using the 
following categories: 
Related:  An AE that follows a reasonable temporal sequence from administration of study 
drug (including the course after withdrawal of the drug), or for which possible involvement of the drug cannot be ruled out, although factors other than the study drug, such as underlying diseases, complications, concomitant drugs, and concurrent treatments, may also be responsible. 
Not Related:  
An AE that does not follow a reasonable temporal sequence from administration of a drug and/or that can reasonably be explained by other factors, such as underlying diseases, complications, concomitant drugs, and concurrent 
treatments.  
 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 49 6.3.1.2.3  Relationship to Study Procedures  
Relationship (causality) to study procedures should be determined for all PTEs and AEs. 
The relationship should be assessed as related if the investigator considers that there is 
reasonable possibility that an event is due to a study procedure. Otherwise, the relationship should be assessed as not related. 
6.3.1.2.4  Start  Date  
The start date of the AE/PTE is the date that the first signs/symptoms were noted by the subject and/or physician. 
6.3.1.2.5  Stop Date  
The stop date of the AE/PTE is the date at which the subject recovered, the event resolved but with sequelae, or the subject died. 
6.3.1.2.6  Frequency  
Episodic AEs/PTE (eg, vomiting) or those which occur repeatedly over a period of consecutive days are considered intermittent. All other events are considered continuous. 
6.3.1.2.7  Action Concerning Study Drug  
• Drug withdrawn: A study drug is stopped due to the particular AE. 
• Dose not changed: The particular AE did not require stopping a study drug. 
• Unknown: Only to be used if it has not been possible to determine what action has 
been taken.  
• Not applicable: A study drug was stopped for a reason other than the particular AE, eg, the study has been terminated, the subject died, or dosing with the study drug was 
already stopped before the onset of the AE. 
• Dose interrupted: The dose was interrupted/held due to the particular AE. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 50 6.3.1.2.8  Outcome 
• Recovered/resolved: Subject returned to baseline status with respect to the AE/PTE.  
• Recovering/resolving: The intensity is lowered by one or more stages: the diagnosis 
or signs/symptoms have lessened/improved; the abnormal laboratory value improved 
but has not returned to the normal range or to baseline; or the subject died from a cause other than the particular AE/PTE with the condition remaining 
“recovering/resolving.”  
• Not recovered/not resolved: There is no change in the diagnosis, signs, or symptoms; the intensity of the diagnosis, signs/symptoms, or laboratory value on the last day of 
the observed study period has worsened from when it started; is an irreversible congenital anomaly; or the subject died from another cause with the particular 
AE/PTE state remaining “ Not recovered/not resolved.”  
• Resolved with sequelae: Subject recovered from an acute AE/PTE but was left with permanent/significant impairment (eg, recovered from a cardiovascular accident but 
with some persisting paresis).  
• Fatal: The AEs/PTEs are consider ed the cause of death.  
• Unknown: The course of the AE/PTE cannot be followed up due to a hospital change 
or residence change at the end of the subject’s participation in the study. 
6.3.1.3  Time Period and Frequency for Collecting AE and SAE 
Information  
6.3.1.3.1  Collection and Reporting of Adverse Events  
Collection of PTEs will commence from the time the informed consent to participate in the 
study has been signed and will continue until the subject is first administered study drug or until screen failure. For subjects who discontinue the study prior to study drug 
administration, PTEs are collected until the subject discontinues study participation. 
Collection of AEs will commence from the time that the subject is first administered study drug (Day 1). Routine collection will continue until the follow-up visit or withdrawal from 
the study. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 51 At each study visit, the investigator will assess whether any subjective AEs have occurred. A 
neutral question, such as “How have you been feeling since your last visit?” may be asked. 
Subjects may report AEs occurring at any other time during the study. Subjects experiencing a serious PTE must be monitored until the symptoms subside and any clinically relevant changes in laboratory values have returned to baseline or there is a satisfactory explanation 
for the change. Nonserious PTEs, related or unrelated to the study procedure, need not be 
followed up for the purposes of the protocol. All subjects experiencing AEs, whether considered associated with the use of the study drug or not, must be monitored until the symptoms subside and any clinically relevant changes in laboratory values have returned to 
baseline or until there is a satisfactory explanation for the changes observed. 
All PTEs and AEs will be documented in the PTE/AE page of the eCRF, whether or not the 
investigator concludes that the event is related to the drug treatment. The following information will be documented for each event: 
• Event term  
• Start and stop date 
• Severity  
• Investigator’s opinion of the causal relationship between the event and administration 
of study drug(s) (related or not related) (not completed for PTEs) 
• Investigator’s opinion of the causal relationship to study procedure(s), including the details of the suspected procedure 
• Action concerning study drug (not applicable for PTEs) 
• Outcome of event  
• Seriousness 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 52 6.3.1.3.2  Collection and Reporting of Serious Adverse Events  
When an SAE occurs through the AE collection period, it should be reported according to the 
following procedure:  
An SAE eCRF must be completed and submitted via Medidata Rave immediately or within 
24 hours of first onset or notification of the event. The information should be completed as 
fully as possible but contain, at a minimum: 
• A short description of the event and the reason why the event is categorized as serious 
• Subject identification number 
• Investigator’s name 
• Name of the study drug(s) 
• Causality assessment  
If the Medidata Rave system is not functioning for any reason, a paper SAE case report form must be completed (in English), signed by the investigator, and faxed to the contact listed 
below. 
The SAE form should be transmitted within 24 hours to  Pharmacovigilance. 
 
 24-Hour Sa fety Contact Information 
 
SAE Hotline:  
SAE Fax:  or  
 
Any SAE spontaneously reported to the investigator following the AE collection period 
should be reported to the sponsor if considered related to study participation. 

Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 53 Investigators are not obligated to actively seek information regarding new AEs or SAEs after 
conclusion of the study participation. However, if the investigator learns of any SAE, 
including a death, at any time after a subject has been discharged from the study, and he/she considers the event to be reasonably related to the study drug or study participation, the investigator must promptly notify the sponsor. Reporting of serious PTEs will follow the 
procedure described for SAEs. 
6.3.1.3.3  Follow -up of SAEs  
If information not available at the time of the first report becomes available at a later date, the 
investigator should update the SAE eCRF and transmit it immediately within 24 hours of 
receipt. Copies of any relevant data from the hospital notes (eg, ECGs, laboratory tests, 
discharge summary, postmortem results) should be provided, if requested. 
All SAEs should be followed up until resolution or permanent outcome of the event. The 
timelines and procedure for follow- up reports are the same as those for the initial report.  
6.3.1.3.4  Safety Reporting to Investigators, IRB/IECs, and Regulatory 
Authorities 
The sponsor designee (contract research organization) will be delegated the responsibility for 
reporting all suspected unexpected serious adverse reactions (SUSARs) and any other 
applicable SAEs to regulatory authorities, investigators, and the IRB/IEC, as applicable. Relative to the first awareness of the event by/or further provision to the sponsor or sponsor’s designee, SUSARs will be submitted to the regulatory authorities (eg, EudraVigilance 
Database, FDA Adverse Event Reporting System) as an expedited report within 7 days for 
fatal and life -threatening events and 15 days for other serious events, unless otherwise 
required. The sponsor designee will also prepare an expedited report for other safety issues 
that might materially alter the current benefit- risk assessment of an investigational medicinal 
product or that would be sufficient to consider changes in the investigational medicinal 
products. 
6.3.1.4  Regulatory Reporting Requirements for SAEs 
Prompt notification by the investigator to the sponsor/sponsor designee of an SAE is essential so that legal obligations and ethical responsibilities toward the safety of s ubjects 
and the safety of a study drug under clinical investigation are met. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 54 The sponsor/sponsor designee has a legal responsibility to notify regulatory agencies about 
the safety of a study drug under clinical investigation. The sponsor/sponsor designee w ill 
comply with regulatory requirements relating to safety reporting to the regulatory authority, 
IRB/IEC , and investigators. 
For all studies except those utilizing medical devices, investigator safety reports must be 
prepared for SUSARs according to regulatory requirements and sponsor policy and 
forwarded to investigators as necessary. 
An investigator who receives an investigator safety report describing an SAE or other 
specific safety information (eg, summary or listing of SAEs) from the sponsor will revi ew 
and then file it and will notify the IRB/IEC, if appropriate, according to local requirements. 
If there is an increase in unexpected SAEs or if there is a change in the frequency and 
character of expected SAEs based on the known safety profile of vonoprazan, further evaluation will be conducted to characterize these events and any impact on benefit/risk. 
Health authorities will be consulted to agree upon the appropriate action to be taken 
regarding the conduct of the study, including no change to the protocol, revision of the safety monitoring plan, suspension of enrollment, or discontinuation of the study. 
6.3.2 Pregnancy  
If any subject is found to be pregnant during the study, she should be withdrawn, and any sponsor-supplied drug (vonoprazan active) should be immediately discontinued. If the pregnancy occurs during administration of active study drug, eg, after Visit 2 or within 2 
weeks of the last dose of active study drug, the pregnancy should be reported immediately, 
using a pregnancy notification form, to the contact listed in Section  6.3.1.3.2. If the subject 
(and LAR, if legally applicable) agrees to the primary care physician being informed, the investigator should notify the primary care physician that the subject was participating in a 
clinical study at the time she became pregnant and provide details of the treatment the subject 
received. All pregnancies will be reported using the pregnancy form and will be followed up to final outcome. The outcome, including any premature termination, must be reported to the sponsor. An evaluation after the birth of the child will also be conducted. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 55 6.3.3 Laboratory Analyses 
See Table  6-4 for the list of clinical laboratory tests to be performed and the SoE 
(Section  13.1) for the timing and frequency. 
• The investigator must review the laboratory report, document this review, and record 
any clinically relevant changes occurring during the study in the AE section of the eCRF. Th e laboratory reports must be filed with the source documents. Abnormal 
laboratory findings that are expected with the underlying disease should not be 
considered clinically significant unless judged by the investigator to be more severe than expected for the subject’s condition. 
• All laboratory tests with abnormal values considered clinically significant during 
participation in the study or within 30 days after the last dose of study drug should be 
repeated until the values return to normal or baseline or are no longer considered clinically significant by the investigator or medical monitor.  
o If such values do not return to normal/baseline within a period of time judged 
reasonable by the investigator, the etiology should be identified, and the 
sponsor notified. 
o All protocol-required laboratory assessments, as defined in Table  6-4, must be 
conducted in accordance with the laboratory manual and the SoE. 
 If laboratory values from non–protocol-specified laboratory assessments performed at the institution’s local laboratory require a change in subject management or are considered clinically significant 
by the investigator (eg, SAE, AE, or dose modification), then the 
results must be recorded in the unscheduled laboratory eCRF. 
All samples will be collected in accordance with acceptable laboratory procedures. Details of these procedures and required safety monitoring will be provided in the laboratory manual. 
All stud y-required laboratory assessments will be performed by a central laboratory. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 56 Table 6- 4 Protocol- Required Safety Laboratory Assessments  
Laboratory 
Assessments  Parameters  
Hematology  • Platelet count 
• RBC count  
• Hemoglobin  
• Hematocrit  
• RBC indices: MCV, MCH  
• Percent reticulocytes  
• WBC count with differential: neutrophils, lymphocytes, monocytes, eosinophils, 
basophils  
Clinical chemistry a • Blood urea nitrogen  
• Creatinine  
• Total and direct bilirubin  
• ALT/SGPT  
• AST/SGOT  
• Alkaline phosphatase  • Total protein  
• Potassium  
• Sodium  
• Calcium  
• Glucose  b  
• GGT  
Routine urinalysis c  • Specific gravity, appearance, color  
• pH, glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocyte esterase  
• Microscopic examination (if blood or protein is abnormal)  
Other screening tests  • Serology (HIV antibody, HBsAg, HCV antibody, HCV viral load RNA [qualitative]), hCG pregnancy test 
d  
ALT:  alanine aminotransferase; AST:  aspartate aminotransferase; GGT:  gamma -glutamyl transferase; 
HBsAg: hepatitis B surface antigen; HCV: hepatitis C virus; HIV:  human immunodeficiency virus; hCG : 
human chorionic gonadotropin; MCH:  mean corpuscular hemoglobin; MCV:  mean corpuscular volume; 
RBC: red blood cell; RNA: ribonucleic acid; SGOT: serum glutamic -oxaloacetic transaminase; SGPT: serum 
glutamic -pyruvic transaminase; WBC:  white blood cell  
a See Section  13.3 for the appropriate guidance on reporting of abnormal liver function tests. For liver 
function test monitoring, see Section  13.3.1. For temporary and permanent discontinuation of study 
drugs  due to abnormal liver function tests, see Section  13.3.2 and Section  13.3.3, respectively. 
b Glucose will be obtained at Visit 1 and at any unscheduled visit.  
c At the discretion of the investigator.  
d    Only female subjects who have experienced menarche will have urine hCG; if the urine hCG test is 
positive confirm with serum hCG.  
 
Investigators must document their review of each laboratory safety report. 
6.3.4 Physical Examinations  
Refer to the SoE (Section  13.1) for the timing and frequency for full and brief physical 
examinations, as well as height and body weight.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 57 A complete  physical examination will include, at a minimum, assessments of the skin, 
cardiovascular, respiratory, gastrointestinal, neurological systems and Tanner staging 
(Section  13.5) . Height and body weight will also be measured and recorded. The subject 
should be dressed in light clothing and  without shoes when the body weight is being 
measured . 
A brief physical examination will include, at a minimum, assessments of the skin, cardiovascular, respiratory, and gastrointestinal systems. 
Investigators should pay special attention to clinical signs related to previous serious 
illnesses.  
6.3.5 Vital Signs  
Refer to the SoE (Section  13.1) for the timing and frequency of vital sign assessments.  
Vital signs will include systolic and diastolic blood pressure, pulse rate, respiratory rate, and 
temperature.  
6.3.6 Electrocardiograms  
Refer to the SoE (Section  13.1) for the timing and frequency of ECG assessments.  
A single, standard 12-lead ECG recording will be made after the subject has been in the 
supine position for at least 5 minutes. ECGs will be read and interpreted centrally by a 
pediatric cardiologist for eligibility during Screening and on Day 14. A single repeat measurement is permitted during screening period for eligibility determination. Assessments will include whether the tracings are normal or abnormal (if abnormal, whether clinically 
significant or not clinically significant).  
6.4 Safety Monitoring Committee  
Based on the well -characterized safety prof ile in adults, a Safety Monitoring Committee is 
not planned for this study. The sponsor and investigators will review safety and tolerability 
data throughout the study. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 58 7 Statistical and Analytical Plan  
This section describes the statistical and analytical methods to be used for the study. 
7.1 Sample Size Calculations  
Approximately 18 subjects are expected to be enrolled with 9 subjects in each dose group. 
Attempts will be made to enroll subjects across the  ≥ 6 to < 12 years  age range. Because this 
is a pharmacokinetic and safety trial with no comparator, there is no power determination affecting the sample size. The sample size of approximately 18 subjects is considered sufficient to assess the pharmacokinetics, safety, and tolerability of vonoprazan in this 
population. Fewer subjects may be enrolled based on preliminary data, if considered 
sufficient to adequately characterize the PK profile.  
7.2 Analysis Sets 
The pharmacokinetic population will include subjects who receive at least 1 dose of study 
drug and have sufficient concentration data to support accurate estimation of at least 1 
pharmacokinetic parameter.  
The pharmacodynamic population will include subjects who receive at least 1 dose of study 
drug and have sufficient pH data to support calculation of pharmacodynamic parameters. 
The safety population will include all subjects who receive at least 1 dose of study drug.  
7.3 Statistical Analysis Methodology  
7.3.1 Pharmacokinetic Analyses  
The individual pharmacokinetic parameter estimates in Table 6 -1 will be summarized 
desc
riptively by vonoprazan dose. 
The fol
lowing pharmacokinetic parameters will be considered the primary endpoints for the 
study: C max,ss, AUC τ, CL/F,  Vz/F. 
7.3.2 Pharmacodynamic Analyses  
Mean pH and the percentage of time above pH 4, 5, and 6 at baseline (Day -1) and Day 7 will 
be summarized for the subset of subjects for whom intragastric pH monitoring is available. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 59 7.3.3 Efficacy Analyses  
The severity of GERD symptoms at baseline and Days 7 and 14, as assessed by the 
investigator, will be summarized overall and by vonoprazan dose. 
7.3.4 Safety Analyses  
Adverse events will be coded by preferred term and system organ class using the latest 
version of the Medical Dictionary for Regulatory Activities (MedDRA). Treatment- emergent 
AEs will be summarized by treatment and overall, as well as by severity and relationship to 
study drug. Serious AEs and AEs leading to discontinuation of study drug will also be 
presented in the dat a listings and summarized by treatment and overall. 
Actual values and changes from baseline for clinical laboratory test results and vital sign 
measurements will be summarized at each time point using descriptive statistics (number of subjects, mean, SD, m edian, minimum, and maximum). Shift tables will be generated for 
clinical laboratory test results.  
7.3.5 Interim Analyses 
No formal interim analyses will be performed in this study.  
However, a popPK analysis of interim data from a subset of subjects may be conducted prior 
to completion of enrollment to assess whether plasma exposure in pediatric subjects aged ≥ 6 
to < 12 years is within the range observed in adults receiving the same dose.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 60 8 Data Quality Assurance  
This study will be conducted according to the International Council for Harmonisation (ICH) 
E6(R2) risk and quality processes described in the applicable procedural documents and Regulation 536/2014 of the European Parliament and of the council of 16 April 2014 on clinical trials on medicinal products fo r human use and repealing Directive 2001/20/EC. The 
quality management approach to be implemented in this study will be documented and will comply with the current ICH guidance on quality and risk management [ DHHS 2018]. The 
sponsor a
ssumes accountability for actions delegated to other individuals (eg, contract 
research organizations).  
8.1 Data Management  
As part of the responsibilities assumed by participating in the study, the investigator agrees to maintain adequate case histories for the subjects treated as  part of the research under this 
protocol. The investigator agrees to maintain accurate eCRFs and source documentation as part of the case histories. These source documents may include laboratory reports and ECG strips.  
Investigative site personnel will e nter subject data into electronic data capture. The analysis 
data sets will be a combination of these data and data from other sources (eg, laboratory 
data).  
Clinical data management will be performed in accordance with applicable sponsor’s standards and data cleaning procedures to ensure the integrity of the data, eg, correcting 
errors and inconsistencies in the data. Adverse event terms will be coded using the MedDRA, 
and concomitant medications will be coded using the World Health Organization Drug Dictionary. 
After the database lock, each study site will receive a file containing all of their site -specific 
eCRF data as entered into Medidata Rave for the study, including full discrepancy and audit 
history. Additionally, a file of all of the study site’s data from the study will be created and sent to the sponsor for storage.  will maintain a duplicate file for their records. In all 
cases, subject initials will not be collected or transmitted to the sponsor.  

Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 61 9 Ethics 
9.1 Institutional Review Board  or Independent Ethics Committee  
Federal regulations, national regulations, and the ICH guidelines require that approval be 
obtained from an IRB/IEC before participation of human subjects in research studies. Before study onset, the protocol, informed consent, advertisements to be used for the recruitment of 
study subjects, and any other written information regarding this study to be provided to the 
subject and/or LAR must be approved by the IRB/IEC. Documentation of all IRB/IEC approvals and of the IRB/IEC compliance with ICH harmonised tripartite guideline, E6: 
Good Clinical Practice (GCP), will be maintained by the site and will be available for review 
by the sponsor or its designee. 
All IRB/IEC approvals should be signed by the IRB/IEC chairperson or designee and must 
identify the IRB/IEC name and address, the clinical protocol by title or protocol number or 
both, and the date approval or a favorable opinion was granted. 
The investigator is responsible for providing written summaries of the progress and status of 
the study at intervals not exceeding 1 year or otherwise specified by the IRB/IEC. The investigator must promptly supply the sponsor or its designee, the IRB/IEC, and, where 
applicable, the institution, with written reports on any changes signific antly affecting the 
conduct of the study or increasing the risk to subjects. 
9.2 Ethical Conduct of the Study  
The study will be performed in accordance with the ethical principles that have their origin in the Declaration of Helsinki, ICH GCP, the protocol, and all applicable regulations. 
All potential serious breaches must be reported to the sponsor or designee immediately. A 
serious breach is a breach of the conditions and principles of GCP in connection with the 
study or the protocol which is likely to affect to a significant degree the safety or physical or 
mental integrity of the subjects of the study or the scientific value of the study. 
9.3 Subject Information and Consent  
A written informed consent in compliance with regulatory authority regulations shall be 
obtained from each subject’s LAR before entering the subject in the study or performing any 
unusual or nonroutine procedure that involves risk to the subject. Participating subjects will 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 62 provide assent as applicable. An informed consent template may be provided by the sponsor 
to investigative sites. If any institution -specific modifications to study -related procedures are 
proposed or made by the site, the consent and assent materials should be reviewed by the 
sponsor or its designee or both before IRB/IEC submission. Once reviewed, the consent and assent materials will be submitted by the investigator to his or her IRB/IEC for review and 
approval before the start of the study. If the ICF or assent form is revised during the course of 
the study, the LAR for e ach active participating subject and the active participating subject (if 
applicable) must sign the revised form as applicable. 
Before recruitment and enrollment, each LAR and prospective subject (if applicable) will be 
given a full explanation of the study and be allowed to read the approved ICF and assent 
form (if applicable). Once the investigator is assured that the LAR and subject (if applicable) understand the implications of participating in the study, the LAR will be asked to give consent for the subject to participate in the study by signing the ICF. If applicable, the subject 
will be asked to give assent by signing the assent form. 
The investigator shall retain the signed original form(s) and give a copy of the signed original 
form(s) to the LAR an d subject (if applicable).  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 63 10 Investigator’s Obligations  
The following administrative items are meant to guide the investigator in the conduct of the 
study but may be subject to change based on industry and government standard operating procedures, working practice documents, or guidelines. Changes will be reported to the IRB/IEC but will not result in protocol amendments.  
The Investigator will also be responsible for providing oversight of the conduct of the study or site, including oversight of all personnel involved in the study, and adherence to all applicable laws and regulations as set forth in the Clinical Trial Agreement.  
Personnel involved in conducting this study will be qualified by education, training and 
experience prior to performing their respec tive tasks.  
10.1 Confidentiality  
All laboratory specimens, evaluation forms, reports, and other records will be identified in a manner designed to maintain subject confidentiality. All records will be kept in a secure 
storage area with limited access. Clinical information will not be released without the written permission of the subject, except as necessary for monitoring and auditing by the sponsor, its designee, the United States Food and Drug Administration (FDA) or any regulatory 
authority(ies), or the IRB/ IEC. 
The investigator and all employees and coworkers involved with this study may not disclose 
or use for any purpose other than performance of the study any data, record, or other unpublished, confidential information disclosed to those individuals for the purpose of the 
study. Prior written agreement from the sponsor or its designee must be obtained for the 
disclosure of any said confidential information to other parties. 
10.2 Financial Disclosure and Obligations  
Investigators are required to provide financial disclosure information to allow the sponsor to submit the complete and accurate certification or disclosure statements required under 21 Code of Federal Regulations (CFR) 54. In addition, the investigator must provide to the sponsor a commitment to promptly update this information if any relevant changes occur 
during the course of the investigation and for 1 year following the completion of the study. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 64 Neither the sponsor nor  is financially responsible for further testing or treatment of any 
medical co ndition that may be detected during the screening process. In addition, in the 
absence of specific arrangements, neither the sponsor nor  is financially responsible for 
further treatment of the subject’s disease.  
10.3 Investigator Documentation  
Prior to beginning the study, the investigator will be asked to comply with ICH E6 8.2 and Title 21 of the CFR by providing the following essential documents, including but not limited to the following: 
• IRB/IEC approval 
• Original investigator -signed investigator agreement page of the protocol 
• Form FDA 1572, fully executed, and all updates on a new fully executed Form 
FDA 1572 for United States sites and equivalent form for non- US sites  
• Curriculum vitae for the investigator and each subinvestigator listed on Form FDA 1572 equivalent form for non- US sites  
• Financial disclosure information to allow the sponsor to submit complete and accurate certification or disclosure statements required under 21 CFR 54. In addition, the investigators must provide to the sponsor a commitment to promptly update thi s 
information if any relevant changes occur during the course of the investigation and 
for 1  year after the completion of the study. 
• IRB/IEC -approved informed consent and assent (if applicable), samples of site 
advertisements for recruitment for this study, and any other written information regarding this study that is to be provided to the subject and LAR 
• Laboratory certifications and normal ranges for any local laboratories used by the 
site, in accordance with 42 CFR 493 
10.4 Study Conduct  
The investigator agrees that the study will be conducted according to the principles of 
ICH E6. The investigator will conduct all aspects of this study in accordance with all 

Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 65 national, state, and local laws or regulations. Study information from this protocol will be 
posted on publicly available clinical trial registers before enrollment of subjects begins.  
10.5 Adherence to Protocol  
The investigator agrees to conduct the study as outlined in this protocol in accordance with 
ICH E6 and all applicable guidelines and regulations. 
10.6 Adverse Events and Study Report Requirements  
By participating in this study, the investigator agrees to submit reports of SAEs to the sponsor and/or IRB/IEC according to the timeline and method outlined in the protocol. In 
addition, the investigator agrees to submit annual reports to the study site IRB/IEC as 
appropriate. 
10.7 Investigator’s Final Report  
Upon completion of the study, the investigator, where applicable, should inform the 
institution; the investigator/institution should provide the IRB/IEC with a summary of the 
study’s outcome and the sponsor and regulatory authority(ies) with any reports required. 
10.8 Records Retention  
Essential documents should be retained until at least 2 years after the last approval of a 
marketing application in an ICH region and until there are no pending or contemplated 
marketing applications in an ICH region or at least 2 years have elapsed since the formal discontinuation of clinical development of the investigational product. These documents 
should be retained for a longer period, however, if required by the applicable regulatory 
requirements or by an agreement with the sponsor. It is the responsibility of the sponsor to inform the investigator/institution as to when these documents no longer need to be retained. 
10.9 Publications  
After completion of the study, the data may be considered for reporting at a scientific 
meeting or for publication in a scientific journal. In these cases, the sponsor will be responsible for these activities and will work with the investigators to determine h ow the 
manuscript is written and edited, the number and order of authors, the publication to which it 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 66 will be submitted, and other related issues. The sponsor has final approval authority over all 
such issues.  
Data are the property of the sponsor and cannot be published without prior authorization 
from the sponsor, but data and publication thereof will not be unduly withheld. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 67 11 Study Management  
11.1 Monitoring  
11.1.1  External Data Monitoring Committee  
An external data monitoring committee will not be used for this study . This is a Phase 1 study 
with 14 days dosing and adverse events will be evaluated on an ongoing basis. Additionally,  
vonoprazan has a well characterized safety profile in adults.  
11.1.2  Monitoring of the Study  
The clinical monitor, acting as the main line of communication between the sponsor (or 
designee) and the investigator and as a representative of the sponsor, has the obligation to 
follow the study closely. In doing so, the monitor will visit the investigator and study site at periodic intervals, in addition to maintaining necessary telephone and letter contact. The monitor will maintain current personal knowledge of the study through observation, review 
of study records and source documentation, and discussion of the conduct of the study with 
the investigato r and personnel. 
All aspects of the study will be carefully monitored, by the sponsor or its designee, for compliance with applicable government regulation with respect to current GCP and current 
standard operating procedures. 
11.1.3  Inspection of Records  
Investigators and institutions involved in the study will permit study-related monitoring, audits, IRB/IEC review, and regulatory inspections by providing direct access to all study 
records. In the event of an audit, the investigator agrees to allow the sponsor, representatives of the sponsor, or a regulatory agency access to all study records. 
The investigator should promptly notify the sponsor and  of any audits scheduled by any 
regulatory authorities and promptly forward copies of any audit reports re ceived to the 
sponsor. 

Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 68 11.2 Management of Protocol Amendments and Deviations 
11.2.1  Modification of the Protocol  
Any changes in this research activity, except those necessary to remove an apparent, 
immediate hazard to the subject, must be reviewed and approved by the sponsor or its designee. Amendments to the protocol must be submitted in writing to the investigator’s 
IRB/IEC for approval before subjects can be enrolled into an amended protocol. 
11.2.2  Protocol Deviations 
The investigator or designee must document and explain in the subject’s source documentation any deviation from the approved protocol. The investigator may implement a 
deviation from, or a change of, the protocol to eliminate an immediate hazard to study subjects without prior IRB/IEC approval. As soon as pos sible after such an occurrence, the 
implemented deviation or change, the reasons for it, and any proposed protocol amendments 
should be submitted to the IRB/IEC for review, to the sponsor for agreement, and to the 
regulatory authorities, if required. 
A dev iation from the protocol is an unintended or unanticipated departure from the 
procedures or processes approved by the sponsor and the IRB/IEC and agreed to by the 
investigator. A significant deviation occurs when there is nonadherence to the protocol by the 
subject or investigator that results in a significant additional risk to the subject. Significant deviations can include nonadherence to inclusion or exclusion criteria, or nonadherence to FDA regulations or ICH GCP guidelines, and may lead to the subject being withdrawn from 
the study (Section 4.2).  
Protocol deviations will be documented by the investigative site staff, the clinical monitor, 
and/or the contract research organization throughout the course of the study. Principal 
investigators will be notified in writing by the monitor of any deviations discovered during a 
monitoring visit. The IRB/IEC should be notified of all protocol deviations they consider reportable in a timely manner.  
11.3 Study Termination  
Although the sponsor has every intention of completing the study, the sponsor reserves the right to discontinue the study at any time for clinical or administrative reasons.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 69 The end of the study is defined as the date on which the last subject completes the last visit 
(includes follow-up visit). 
11.4 Final Report  
Whether the study is completed or prematurely terminated, the sponsor will ensure that the 
clinical study reports are prepared and provided to the regulatory agency(ies) as required by 
the applicable regulatory requirement(s). The sponsor will also ensure that the clinical study 
reports in marketing applications meet the standards of the ICH harmonised tripartite guideline E3: Structure and content of clinical study reports.  
Where required by applicable regulatory requirements, an investigator signatory will be 
identified for the approval of the clinical study report. The investigator will be provided 
reasonable access to statistical tables, fi gures, and relevant reports and will have the 
opportunity to review the complete study results. 
The sponsor will submit to clinical trial registries a summary of the results of the clinical trial 
and where applicable a summary that is understandable to a l ayperson, and the clinical study 
report health authorities, within 6 months after the end of the study. The investigator is encouraged to share the summary results with the LARs and study subjects, as appropriate.  
 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 70 12 Reference List  
Cezard JP. Managing gastr o-oesophageal reflux disease in children. Digestion 
2004;69 Suppl 1:3-8. 
Department of Health and Human Services (DHHS), Food and Drug Administration (FDA), 
Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and 
Research (CBER) . Guidance for industry: E6(R2) Good Clinical Practice: Integrated 
Addendum to E6(R1) March 2018. [cited 2021 Jan 12] Available from: 
https://www.fda.gov/media/93884/download  
Engevik AC, Kaji I, Goldenring JR. The physiology of the gastric parietal cell. Physiol 
Rev 2020;100(2):573-602. 
Facius A. Population PK Analysis to Support the Paediatric Development of V onoprazan 
2023. 
Gilger MA, El -Serag  HB, Gold BD, et al. Prevalence of endoscopic findings of erosive 
esophagitis in children: a population-based study. J Pediatr Gastroenterol Nutr 
2008;47(2):141-6. 
Gold BD, Freston JW. Gastroesophageal reflux in children: pathogenesis, prevalence, 
diagnosis, and role of proton pump inhibitors in treatment. Paediatr Drugs 
2002;4(10):673-85. 
Gold BD, Gunasekaran T, Tolia V , et al. Safety and symptom improvement with 
esomeprazole in adolescents with gastroesophageal reflux disease. J Pediatr Gastroenterol 
Nutr 2007;45(5):520-9. 
Gremse D, Winter H, Tolia V , et al. Pharmacokinetics and pharmacodynamics of 
lansoprazole in children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2002;35:S319-26. 
Gunasekaran T, Gupta S, Gremse D, et al. Lansoprazole in adolescents with gastroesophageal 
reflux disease:  pharmacokinetics, pharmacodynamics, symptom relief efficacy, and 
tolerability. J Pediatr Gastroenterol Nutr 2002;35 Suppl 4:S327-35. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 71 James L, Walson P, Lomax K, et al. Pharmacokinetics and tolerability of rabeprazole sodium 
in subjects aged 12 to 16 years with gastroesophageal reflux disease: an open-label, single- 
and multiple -dose study. Clin Ther 2007;29(9):2082-92. 
Jenkins H, Sakurai Y , Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a 
novel potassium- competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 
2015;41(7):636-48. 
Kukulka M, Wu J, Perez MC. Pharmacokinetics and safety of dexlansoprazole MR in 
adolescents with symptomatic GE RD. J Pediatr Gastroenterol Nutr 2012;54(1):41-7. 
Kukulka M, Nudurupati S, Perez MC. Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease. Clin Exp Gastroenterol 2014;7:461-71.  
Li J, Zhao  J, Hammer -Maansson JE, et al. Pharmacokinetic properties of esomeprazole in 
adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: a 
randomized, open label study. Clin Ther 2006;28(3):419-27. 
Nelson SP, Chen EH, Syniar GM, Christoffel KK. Prevalence of symptoms of 
gastroesophageal reflux during childhood: a pediatric practice- based survey. Pediatric 
Practice Research Group. Arch Pediatr Adolesc Med 2000;154(2):150-4. 
Rosen R, Vandenplas Y , Singendonk M, et al. Pediatric gastroesophageal reflux clinical 
practice guidelines: joint recommendations of the North American Society for Pediatric 
Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric 
Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2018;66(3):516-54. 
Sakurai Y , Mori Y , Okamoto H, et al. Acid -inhibitory effects of vonoprazan 20 mg compared 
with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects-a randomised 
open- label  cross -over study. Aliment Pharmacol Ther 2015;42(6):719-30. 
Scarpignato C, Hunt RH. The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Curr Opin Gastroenterol 2019;35(4):344–55. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 72 Scott DR, Munson KB, Marcus EA, Lambrecht NW, Sachs G. The binding selectivity of 
vonoprazan (TAK -438) to the gastric H+, K+ - ATPase. Aliment Pharmacol Ther 
2015;42(11-12):1315-26. 
Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. 
J Neuro gastroenterol Motil 2013;19(1):25-35. 
Tolia V , Bishop PR. Tsou VM, et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5- 11 years) with symptomatic gastroesophageal reflux disease. J Pediatr Gastroentero l Nutr 2006;42(4):384-91. 
Vakil N, van Zanten SV , Kahrilas P, Dent J, Jones R, Global Consensus Group. The Montreal 
definition and classification of gastroesophageal reflux disease: a global, evidence- based 
consensus. Am J Gastroenterol 2006;101(8):1900-20. 
Zannikos PN, Doose DR, Leitz GJ, et al. Pharmacokinetics and tolerability of rabeprazole in 
children 1 to 11 years old with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 
2011;52(6):691-701. 
Zhao J, Li J, Hammer-Maansson JE, et al. Pharmacokinetic properties of esomeprazole in 
children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, 
open-label study. Clin Ther 2006;28(11):1868-76. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 74 a For subjects participating in the pharmacodynamic substudy, Visit 2 (Day - 1) and Visit 6  (Day 8)  are only required for 
subjects undergoing gastric pH monitoring if clinically indicated at select sites. pH monitoring will be conducted on 
Day -1 for 24 hours and on Day 7 for 24 hours. pH probes would be placed on Days -1 and 7 and removed on Days 1 
and 8.  
b At an unscheduled visit, the following procedures are to be completed with additional procedures at the investigator’s discretion: a brief physical examination, vital sign measurements, concomitant medication assessment, AE assessment, and clinical laboratory tests. If the visit results in premature termination, then all procedures outlined for the final visit should be performed.  
c Informed consent will be signed by the subject’s legally authorized representative prior to any activity in the study. Subject assent (if applicable) may be obtained as required per site guidelines.  
d A complete physical examination will be performed at screening (at minimum, assessment of skin, cardiovascular, respiratory, gastrointestinal, neurological systems and Tanner staging). A brief physical examination will be performed 
at other visits (at minimum, assessment of skin, cardiovascular, respiratory, and gastrointestinal systems). Interim 
physical examinations may be performed at the discretion of the investigator, if necessary, to evaluate AEs or clinical laboratory abnormalities.  
e Vital signs will include systolic and diastolic blood pressure, pulse rate, respiratory rate, a nd temperature.  
f Height collected only at screening.  
g Hepatitis B surface antigen, hepatitis C virus antibody, and HIV type 1 and 2 antibodies.  
h Clinical laboratory testing will include hematology, serum chemistry, and urinalysis (if deemed necessary by  the PI). 
Blood draws should follow vital signs or electrocardiograms.  
i Only female-born subjects who have reached menarche, will require guidance on avoidance of pregnancy and urine or serum hCG; if urine hCG is positive, confirm with serum hCG.  
j Singl e 12-lead electrocardiogram recordings will be made after the subject has been in the supine position for at least 5 
minutes at screening. A pediatric cardiologist will interpret the ECG for eligibility and any abnormality. A single repeat measurement is permitted at screening for eligibility determination after the read by a pediatric cardiologist. 
Assessments should include comments on whether the tracings are normal or abnormal (if abnormal, whether clinically 
significant or not clinically significant). An ECG will be collected at the final visit and interpreted by a pediatric cardiologist.  
k Subject will be randomized to study treatment after all eligibility criteria have been met.  
l Study drug will be administered in the clinic on Days  1, 7, and 14. Study drug should be taken every day between 7 and 
10 am preferably prior to eating any breakfast or food. Study drug for at home administration will be dispensed on Day 
1 (to be taken on Days 2 to 6) and Day 7 (to be taken on Days 8 to 13). At home, parents/ caregivers will administer 
study drug to subjects. Clinic staff will review instructions with parents/LARs for administering study drug at home 
and completing the Study Drug Reminder Card. Phone call reminders may be conducted as required.  
m Blood samples  for PK analysis of vonoprazan in plasma will be collected on Days 7 and 14. On Day 7 days, one pre -
dose sample will be collected prior to the morning administration of vonoprazan along with two additional samples collected after drug administration: one b etween 0.5 to 1.5 hours post -dose and one between 2.5 to 3.5 hours post -dose. 
On Day 14 days, one pre -dose sample will be collected prior to the morning administration of vonoprazan along with 
two additional samples collected after drug administration: one between 1 to 2 hours post -dose and one between 3 to 4 
hours post -dose. The exact time of each pharmacokinetic sample should be recorded in the source and eCRF.  
If a subject terminates early, an attempt should be made to collect one blood sample if it can  be collected within 24 
hours following the last dose of study drug. The exact date and time of the early termination sample must be recorded.  
n Collection of pretreatment events will start after the informed consent form has been signed. Adverse events wi ll be 
assessed from time of informed consent signing until the follow -up visit and should be followed until they are resolved, 
stable, or judged by the investigator to be not clinically significant.  
 
 
 
  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 75 13.2 Appendix  2: Contraceptive Guidance  
Contraception Guidance: 
From  signing of informed  consent, throughout the duration of the study, and for 2 weeks  after 
the last dose of study drug, female subjects  of childbearing potential*  who are sexually  active 
with a nonsterilized  male partner** must use adequate contraception. In addition, they must 
be advised not to donate ova during this period. 
*Females NOT of childbearing potential are defined as those who are premenarchal, 
have been surgically sterilized (hysterectomy, bilateral oophorectomy, or tubal ligation) or who are postmenopausal (eg, defined as at least 1 year since last regular 
menses with a follicle -stimulating hormone level >40 I nternational units per liter  or at 
least 5 years since last regular menses, confirmed before any study drug is 
implemented).  
**Sterilized males should be at least 1 -year post vasectomy and should have 
confirmed that they have obtained documentation of the absence of sperm in the ejaculate.  
Note: If the childbearing potential of a subject changes after start of the study (eg, a 
premenarchal female subject experiences menarche) or the risk of pregnancy changes (eg, a 
female subject who is not heterosexually active becomes active), the p articipant must discuss 
this with the investigator, who should determine if the female subject must begin a highly effective method of contraception or a male participant must use a condom. 
Birth Control: Birth control methods considered acceptable for this study include: 
Barrier methods (each time that you have intercourse) : 
• Male condom PLUS spermicide 
• Cap (plus spermicidal cream or jelly) PLUS male condom and spermicide 
• Diaphragm (plus spermicidal cream or jelly) PLUS male condom and spermicide  
Intrauterine Devices  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 76 • Copper T PLUS condom or spermicide 
• Progesterone T PLUS condom or spermicide 
Hormonal Contraceptives 
• Implants  
• Hormone shot/injection 
• Combined pill 
• Minipill  
• Patch  
• Vaginal ring PLUS male condom and spermicide 
During the course of the study, serum human chorionic gonadotropin ( hCG)  will be 
performed at screening and regular urine hCG pregnancy tests will be performed only for 
women of childbearing potential. Subjects will receive continued guidance with respect to the avoidance of pregnancy as part of the study procedures (Section 13.1). Female subjects must have a negative urine hCG pregnancy test on Day -1 prior to study drug dispensation. 
  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 77 13.3 Appendix 3: Liver Function Tests  
13.3.1  Liver Function Test Monitoring  
Liver function will be carefully monitored throughout the study. Additional monitoring may 
be necessary and is recommended for subjects with abnormal LFTs. 
If subjects with normal baseline ALT or AST levels experience ALT or AST >3 × ULN and a 
2-fold increase above baseline, follow- up laboratory tests (at a minimum, serum alkaline 
phosphatase, ALT, AST, total bilirubin, gamma-glutamyl transferase (GGT), and international 
normalized ratio  [INR]) should be repeated within a maximum of 7 days and preferably 
within 48 to 72 hours after the abnormality was found. 
If subjects with normal baseline ALT or AST levels experience ALT or AST >8  × ULN, 
follow-up laboratory tests (at a minimum, serum alkaline phosphatase, ALT, AST, total 
bilirubin, GGT, and INR) should be repeated within a maximum of 48 hours after the 
abnormality was found. 
13.3.2  Considerations for Temporary Discontinuation of Study Drug  
If the ALT or AST levels remain elevated >3 × U LN in subjects with normal baseline ALT or 
AST levels and a 2 -fold increase above baseline OR  if the ALT or AST levels remain 
elevated >5 × ULN in subjects with elevated baseline ALT or AST levels on 2 consecutive 
occasions, the investigator must contact the medical monitor to discuss additional testing, recommended monitoring, possible temporary discontinuation of study drug, and possible alternative etiologies.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 78 13.3.3  Permanent Discontinuation of Study Drug  
If any of the circumstances occur as mentioned in Table  13-1 at any time during treatment, 
the study drug should be permanently discontinued: 
Table 13-1 Abnormal L iver Function Criteria for Permanent Discontinuation of 
Study Drug  
Subject Baseline Aminotransferases  Criteria for Discontinuation of Study Drug  
Normal ALT or AST at baseline (all subjects)  • ALT or AST >8 × ULN  
• ALT or AST >5 × ULN and persists for more than 
2 weeks  
• ALT or AST >3 × ULN AND a 2-fold increase above 
baseline value in conjunction with elevated total bilirubin >2 × ULN or  INR >1.5  
• ALT or AST >3 × ULN AND a 2-fold increase above 
baseline value with appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)  
ALT: a lanine aminotransferase; AST: aspartate aminotransferase; INR: international normalized ratio; 
ULN:  upper limit of normal  
 
In each of these instances, appropriate clinical follow -up should be instituted (including 
repeat laboratory tests) until a satisfactory conclusion (ie, until the AE resolves, the 
laboratory value returns to baseline, or the condition becomes stable). 
If a subject meets the liver safety criteria and must be discontinued from study drug, the 
subject will continue to be followed per the protocol schedule until the study is completed. If the subject r efuses to return for the study visits, telephone visits may be conducted; 
however, this is not preferred or recommended. The reason for discontinuation of study drug 
should be listed as an LFT abnormality. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 79 If any of the above circumstances occur at any tim e during the study, the abnormality should 
be documented as an SAE, and a Liver Function Test Increase Form completed and sent to:  
Pharmacovigilance  
 
 
 
24-Hour Safety Contact Information 
SAE Hotline:  
SAE Fax:  or  
 
13.3.4  Re-initiation of Study Drug  
If the study drug is discontinued due to any of the scenarios provided above, study drug must 
not be re- initiated without consultation with the medical monitor.  
  

Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 80 13.4 Appendix 4: Questionnaires  
13.4.1  GERD Symptom  Assessment -Investigator  
The following 4 symptoms of GERD will be evaluated, as defined below when asked of 
children 9 to 12 years of age.  
Symptom  Definition  
Heartburn  Hurting or burning in the stomach, chest or thro at  
V omiting  Something coming out of your mouth (throw -up) 
Acid regurgitation  Food come up from your stomach to your mouth  
Trouble eating  Ate less than usual, did not want to eat, did not want to eat certain 
foods because of hurting or burning 
 
The following 4 symptoms of GERD will be evaluated, as defined below when asked of 
parents of children 6 to 8 years of age if the child reported or they observed any of the 
following behaviors. 
Symptom  Definition  
Heartburn  Hurting or burning in the stomach, chest or throat  such as holding 
his/her stomach/chest/throat, lying in curled up position, crying, 
acting fussy, or other behaviors 
V omiting  Something coming out of the mouth  
Acid regurgitation  Partially digested foo d or stomach contents coming up in their 
mouth 
Trouble eating  Refused to eat anything, ate less than usual, refused to eat certain 
foods because of hurting or burning or stomach contents coming up 
in their mouth  
 
  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 81 The maximum severity of each GERD symp tom occurring during the 7 days prior to the 
study visit will be assessed, as detailed below.  
Severity  Definition  
None  No symptom  
Mild  Symptom did not last long and was easily tolerated  
Moderate  Symptom caused discomfort and/or interrupted usual activities 
(including sleep) 
Severe  Symptom caused great interference with usual activities and may 
have been incapacitating (including sleep) 
Very severe  Symptom caused intense and constant discomfort and/or marked 
interference with usual activities (in cluding sleep) 
 
  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 82 13.5 Appendix 5: Tanner Staging  
Tanner Staging will be reported based on the following criteria:  
 
 
  

Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 83 13.6 Appendix 6: National Center for Health Statistics Clinical Body 
Weight Charts with 5th and 95th Percentiles  
13.6.1   Girls 
 

Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 84 13.6.2   Boys 
   

Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 85 13.7 Appendix 7: Protocol Amendments 
In this section, all affected protocol sections are detailed; the sequence of the sections follows 
the structure of the original protocol. Additions to the study protocol are shown in red and deletions are shown in strike- through text. Corrections of obvious typing errors or omissions 
are not highlighted.  
Globally “with body weight ≥  30 kg” was removed and is not highlighted below unless other 
information changed within the section.  
13.7.1  Protocol Amendment 1 
Synopsis (EU Trial Number)  2022-003228-42  Synopsis (Study Sites)  Approximately 20 to 25 sites in the United States and Europe 
 
Synopsis (Study Design and Interventions )  
This is a Phase 1, uncontrolled, randomized, open- label
 , parallel -group, multiple-dose study 
in children ≥ 6 to < 12 years of age  with a body weight ≥ 30 kg who have symptomatic 
GERD. Subjects will be scre ened for up to 28 days. Successfully screened subjects will be 
randomized to receive 10 or 20 mg of vonoprazan QD for 14 days. Approximately A total of 
18 subjects are expected to be enrolled in the study. 
Blood samples for pharmacokinetic testing will be collected on Days 7 and 14. Select sites 
will pe
rform gastric pH monitoring in subjects deemed clinically indicated by the principal 
investigator.  
Subjects undergoing gastric pH monitoring will be confined to the clinic for testing. Gastric 
pH will be mon itored for 24 hours beginning on Day -1 and on Day 7. 
The study will include 3 periods: 
Screening Period (≤ 4 weeks):  Subjects will undergo screening assessments to determine 
study eligibility, and baseline assessments will be performed. If all eligibility criteria are met, 
the subject will be randomized and enter the Treatment Period. 
Treatment Period (Day 1 to Day 14):  Subjects will be randomized to receive vonoprazan 
10 mg or vonoprazan 20 mg QD. 
Follow -up Period:  A safety follow-up phone call will occur 2 weeks after the last dose of 
study drug to assess adverse events (AEs). A subject will be considered to have compl eted the study if the subject completes the 
Treatment Period and the safety follow-up phone call. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 86 Following the last dose of study drug or early discontinuation, the subject will be transitioned 
to local standard of care in accordance with each site’s prespecified process . 
Synopsis ( Pharmacokinetic Assessments  (Primary Endpoints) )  
The primary vonoprazan pharmacokinetic endpoints will include the following steady state parameters from data collected on Day 7 and Day 14: 
• Maximum observed drug concentration at steady state (C
max,ss) 
• Area under the plasma concentration -time curve during the dosing interval τ ( AUC τ) 
• Apparent oral clearance (CL /F) 
• Apparent volume of distribution (V z/F) 
 
Synopsis (Study Drug, Dosage, and Route of Administration) Open -label study drug (vonoprazan 10 mg or vonoprazan 20 mg) to be taken orally QD for 
14 days
 (Day 1 through Day 14). All study drug doses are to be taken  on an empty stomach 
preferably prior to eating any breakfast or food with approximately 240 mL (8 oz) water 
between 7 and 10 am each day. 
Synopsis ( Ethical Considerations ) 
C
linical studies in adults with GERD have shown a positive benefit -risk for vonoprazan. This 
study is anticipated to provide benefits to children ≥ 6 to < 12 years of age with symptomatic 
GERD and risks similar to those observed with vonoprazan in adults. This study is needed to identify doses to be used in future trials in children ≥ 6 to < 12 years of age.  
The study was designed to minimize the number of blood samples and visits to investigate the pharmacokinetics and safety in this population. 
 Synopsis (Sample Size)  Approximately 18 subjects will be enrolled with 9 subjects in each dose group. Attemp
 ts will 
be made to enroll subjects across the ≥ 6 to < 12 years age range . Because this is a 
pharmacokinetic and safety trial with no comparator, there is no power determination 
affecting the sample size. The sample size of approximately 18 subjects is considered sufficient to assess the pharmacokinetics, safety, and tolerability of vonoprazan in this population. Fewer subjects may be enrolled based on preliminary data, if considered sufficient to adequately characterize the PK  pharmacokinetic  profile  
 
Synopsis (Statistical Methods) Pharmacokinetic Endpoints: 
Individual pharmacokinetic parameter estimates will be summarized descriptively by 
vonoprazan dose.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 87 Efficacy  and Pharmacodynamic Endpoints: 
The severity of GERD symptoms at screening and Days 7 and 14, as assessed by the 
investigator, will be summarized overall and by vonoprazan dose. 
Pharmacodynamic Endpoints: 
Mean pH and the percentage of time above pH 4, 5, and 6 at baseline (Day -1) and Day 7 will 
be summarized for the subset of subjects for whom intragastric pH monitoring is available. 
Safety:  
Adverse events will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA). The number and percentage of subjects experiencing treatment -emergent AEs 
will be summarized by MedDRA system organ class and preferred term overall, by severity, and by relationship to study drug for each treatment group.  
Clinical laboratory tests, electrocardiograms, and vital signs will be summarized with 
descriptive statistics at each time point by treatment group.  
 
Introduction (Section 1.0) V onoprazan belongs to a new class of acid-inhibitory agents called potassium- competitive 
acid blockers (PCABs). In the United States, vonoprazan in combination with amoxicillin 
and in combination with amoxicillin and clarithromycin have been approved for t he 
treatment of Helicobacter pylori  infection in adults. V onoprazan is being developed for the 
treatment of heartburn in patients with symptomatic non-erosive gastroesophageal reflux disease (sGERD), healing of all grades of erosive esophagitis (EE) and relief of heartburn and maintenance of healing of all grades of EE and relief of heartburn. 
In countries other than the United States, vonoprazan has been studied in other gastric acid-
related diseases such as healing of gastric and duodenal ulcers, and for the prevention of 
recurrence of gastric or duodenal ulcer during nonsteroidal anti-inflammatory drug or aspirin administration. V onoprazan has received regulatory approval for adults in Japan, Russia, and other countries in Asia and Latin America for a variety of indications, including the healing 
of erosive esophagitis and maintenance of healing of erosive esophagitis. Vonoprazan is not 
currently approved for use in pediatric patients in any country.  
Phathom Pharmaceuticals, Inc. licensed the exclusive rights from Takeda Pharmaceutical 
Company Limited (Takeda) to develop, manufacture, and commercialize vonoprazan in the 
United States, Europe, and Canada. 
 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 88 Study Rationale (Section 1.1) 
The purpose of this study is to determine a dose of vonoprazan in childr en aged ≥  6 to < 12 
years with body weight ≥ 30 kg with symptomatic gastroesophageal reflux disease (GERD) 
that provides an exposure similar to the exposures in adults after administration of 
vonoprazan 10 or 20 mg once daily (QD). Like proton pump inhibitors, vonoprazan is expected to provide benefit in pediatric patients with GERD.  
 
Vonoprazan (
Section 1.2.2) 
The gastric hydrogen, potassium–adenosine triphosphatase (H+, K+-ATPase), also known as 
the proton pump, is responsible for acid secretion from par ietal cells in the stomach. It is 
inactive in the cytosol but relocates from the cytosol to the secretory membrane of the parietal cells when food is present in the stomach, thereby becoming active and pumping 
H+ ions out of the cells and into the canaliculi in exchange for K+ ions. It represents an 
attractive pharmacological target since it is the final step of the acid secretion process.  
Two classes of pharmaceuticals, with distinct mechanisms of action for inhibiting the gastric proton pump, have been developed for clinical application: PPIs and PCABs. As a PCAB, 
vonoprazan has a unique mechanism of action and pharmacokinetics relative to PPIs: 
• Acid activation and stability: Conventional PPIs are prodrugs, which are activated by 
ac
id and covalently bind to the H+, K+- ATPase; however, activated PPIs are not 
stable in acidic conditions. In contrast, vonoprazan does not require acid activation, is stable in acidic conditions, and has a more durable effect. Further, vonoprazan is 
rapidly protonated in the par ietal cell canaliculi, which concentrates the drug 
proximal to the H+, K+- ATPase [ Scar
pignato 2019].  
• Activity against proton pumps: V onoprazan inhibits acid secretion by competitively 
inhi
biting the binding of potassium ions to the H+, K+- ATPase. V onopraza n may 
selectively concentrate in the parietal cells in both the resting and stimulated states 
and binds to the active pumps in a noncovalent and reversible manner. In contrast, PPIs covalently bind H+, K+- ATPase only when the pump is active, as an acidic 
environment is required for the activation and accumulation of PPIs in the parietal cell [ Scott  2015
].  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 89 • V onoprazan maintains acid control over 24 hours with QD dosing [ Engevik 2020]. 
V onoprazan can also be dosed in the presence or absence of food, while mos t PPIs  
require dosing before a meal to optimize their acid suppressant effect because 
activated pumps are at their highest level post -prandially due to activation of pumps 
by the meal [ Shin 2013].  
• Extended half- life: The mean plasma half -life is typically 7 to 8 hours after single and 
multiple QD administration of vonoprazan 20 mg (TAK- 438_107). This is 
significantly longer than the half- life of conventional PPIs (<2 hours) [ Shin 2013
]. 
• Metabolism: V onoprazan is metabolized by a combination of cytochrome P450 
(C
YP) isoforms including CYP3A4/5, which does not have a high degree of genetic 
polymorphism as compared with CYP2C19, which is the primary enzyme responsible for the metabolism of PPIs [ Shin 2013].  
T
hese unique aspects of the vonoprazan mechanism of action and pharmacokinetics relative 
to PP
Is translate into greater magnitude and duration of gastric acid suppression, which are 
reflected in the pharmacodynamic profile [ Jenkins
 2015; Sakurai  2015].  
The
 pharmacokinetic and pharmacodynamic profiles of vonoprazan were assessed in 
multiple studies, including Study TAK-438_107, which showed rapid rise in pH following 
vonoprazan administration and a dose response for percent time above pH 4. The mean 
percentage of time above pH  4 on Day 1 for vonoprazan 10 mg, 20 mg, and 40 mg were 
43%, 63%, and 86%, respectively, and by Day 7 were 60%, 85%, and 93%, respectively 
[Jenkins
 2015].  
Takeda conducted 8 short- term clinical studies in adults with EE (5  studies) and symptomatic 
non-erosive GERD (3 studies) with treatment durations of 2 to 8 weeks. In addition, Takeda conducted 3 studies of maintenance of healing of EE with treatment durations of 24 to 52 weeks. V onoprazan is approved in multiple countries outside of the United States for the treatment of adults for reflux (erosive) esophagitis (for healing: vonoprazan 20 mg QD up to 
4 weeks or, if insufficient effect, 8 weeks; for maintenance: 10 mg QD or, if insufficient effect, 20 mg QD). 
The safety profile of vonoprazan in Phase 3 studies of adults across indications showed no 
evidence of a dose -related increase in adverse effects with vonoprazan from 5  mg to 40 mg 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 90 QD. As of 25 December 20212022, the global cumulative post-marketing patient exposure to 
vonoprazan is estimated to be approximately 7097 million patients.  
Overall, with vonoprazan’s pharmacological profile of rapid, potent, and sustained elevations 
of gastric pH, vonoprazan offers the potential to be a highly effective treatment option for children with symptomatic GERD.  
 
Justification fo r Dose (Section 1.3) 
The proposed pediatric doses are selected to approximate equivalent adult exposures 
foll
owing administration of vonoprazan 10 or 20 mg QD in children  aged  pediatric patients  ≥ 
6 to < 12 years of age with body weight of ≥ 30 kg.  
The proposed doses are based on simulations using a an updated population pharmacokinetic 
(popPK) model [Facius 2023] . The 2-compartment linear popPK model for vonoprazan was 
developed with adult pharmacokinetic  data from  13 healthy subjects aged 18 to 54 years who 
participated in 9  studies in healthy volunteers, 1 study in EE patients specifically selected to 
enable the extrapolation and 1 study in GERD patients.characterization of the disposition of 
vonoprazan in pediatric subjects . The final dataset consisted of  1,179354 subjects ( 769205 
Asian and 410149 Western) with  8010 plasma concentration observations. 
 As planned, an analysis of interim PK data from the first adolescent subjects aged 12 to 17 years randomized in Study VPED-102 was performed using the updated popPK model. Interim data from VPED -102 was combined with adult data from the updated popPK model 
to investigate potential differences in the pharmacokinetic properties of vonoprazan between adolescents and adults. Individual predicted AUC
ss values for the 8 adolescent subjects with 
symptomatic GERD included in the preliminary analysis were within the  range expected 
from healthy adults at their respective doses and no obvious effect of age was observed. 
Model assessments indicated the updated popPK model was working well in adolescents and 
substantiated the usefulness of  For the pediatric dose simulations using the popPK model to 
select doses  for vonoprazan was updated to incorporate body size and maturation correction 
factors, younger pediatric subjects .   
For predicting the  appropriate to predict doses in pediatric subjects aged ≥ 6 to <12 years, 
simula tions were performed using the updated popPK model for  vonoprazan exposure in 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 91 infants, children, and adolescents (PopPK Simulation Memo).and were summarized by both 
age and body weight . For reference, all boys and girls aged ≥ 6 to < 12 years who have a 
body weight between the 5th and 95th percentiles would have a body weight between 15 and 
65 kg. Different model assumptions in terms of  (i) the allometric weight scaling exponent (as 
estimated  (none)  in the adult data or fixed at 0.75) and (ii) if or if not to correct for enzyme 
maturation in infants 2) were compared.  
The resulting models were updated model was  used to simulate posterior distributions of area 
under the drug concentration- time curve at steady state (AUC ss) in both adults and ped iatrics  
pediatric subjects aged ≥6 to <12 years or with a body weight of 15 to 65 kg for a series of 
pediatric candidate doses. Matching pediatric doses were selected to limit the predicted 
percentage of pediatrics pediatric subjects with an exposure exceeding the adult reference 
exposure (median AUC ss) at 50  to 60%.  
For children aged ≥ 6 to < 12 years  or with a  body weight ≥ 30of 15 to 65 kg, each of the 
four models simulations gave similar exposure predictions, thereby suggesting that the 
selected doses for these pediatric patients (10 and 20 mg) should result in a majority of exposures that are within the 95% prediction interval in adults for both the 10 and 20 mg 
targeted doses.  
Study Objectives and Endpoints (Section 2) 
Study objectives with corresponding endpoints are presented in Table 2 -
1. 
Table 2-1 Study Objectives and Endpoints  
Objectives  Endpoints  
Primary  
• To evaluate the pharmacokinetic profile of 
vonoprazan (10 or 20 mg QD) in children ≥ 6 to 
< 12 years of age with body weight of ≥ 30 kg 
who have symptomatic GERD.  • Cmax,ss, AUC τ, CL/F, V z/F from data collected on 
Days 7 and 14.  
Safety  
• To evaluate the safety of vonoprazan (10 or 20 
mg QD) in children ≥ 6 to < 12 years of age with body weight of ≥ 30 kg  who have 
symptomatic GERD.  • Adverse events  
• Laboratory test values (hematology, serum chemistry, urinalysis*)  
• Electrocardiograms (ECGs)  
• Vital signs  
Exploratory  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 92 Table 2-1 Study Objectives and Endpoints  
Objectives  Endpoints  
• To evaluate symptom relief and 
pharmacodynamics of vonoprazan (10 or 20 
mg) in children ≥ 6 to < 12 years of age  with 
body weight of ≥ 30 kg  who have symptomatic 
GERD.  • The severity of GERD symptoms at baseline and 
Days 7 and 14, as assessed by the investigator  
• Mean pH and % time above pH 4, 5, and 6 at baseline and Day 7 in the subset of subjects for whom intragastric pH monitoring is performed 
when clinically indicated per the investigator.  
AUC τ: area under the drug concentration- time curve during the dosing interval τ; CL/F: oral clearance; C max,ss: 
maximum drug concentration at steady- state; ECGs; electrocardiograms; GERD: gastroesophageal reflux 
disease; QD: once daily; V z/F: apparent volume of distribution  
* Urinalysis is only required if deemed necessary by the investigator.  
 
Study Design (Section 3.1) This is a Phase 1, uncontrolled, randomized, open- label
 , parallel-group, multiple-dose study 
in children aged ≥ 6 to < 12 yea rs with body weight of ≥ 30 kg who have symptomatic 
GERD. A total of approximately 18 subjects will be enrolled.  
Blood samples for pharmacokinetic testing will be collected on Days 7 and 14. Sel ect si tes 
will perform gastric pH monitoring in subjects deemed clinically indicated by the principal 
investigator. Gastric pH will be monitored for 24 hours beginning on Day -1 and on Day 7. 
Following completion of study drug dosing on Day 14 or early discontinuation, the subject 
will be transitioned to local standard of care for 14 days during the Follow-up Period. Note, 
standard of care does not include the use of study drug but can include other acid suppressant 
agents.  
A schematic diagram of the overall study design is presented in Figure 3.1. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 94 The study will include 3 periods ( see the schedule of events [SoE] in Section  13.1 for 
details ). 
S
creenin
g Period (≤ 4 weeks):  Subjects will undergo screening assessments to determine 
study eligibility, and baseline assessments will be performed. If all eligibility criteria are met, 
the subject will be randomized and enter the Treatment  Period. 
Treatment Period (Day 1 to Day 14): Subjects will be randomized to receive 1 of 2 vonoprazan doses (10 mg QD or 20 mg QD) for 14 days. 
Follow -up Period (2 weeks): A safety follow-up visit phone call will occur 2 weeks after the 
last dose of study drug to assess adverse events (AEs). Following completion of study drug 
dosing or early discontinuation, the subject will be transitioned to local standard of care for 
14 days. 
End-of-study definition:  A subject will be considered to have completed the stu dy (up to 8 
weeks, including 4 weeks of screening, 2 weeks of treatment and 2 weeks of safety follow-
up) if the subject completes the Treatment Period and the safety follow-up visit phone call. 
 
Selection of Study Population (Section 4.1) 
This study will b e conducted at approximately 20 to 25 sites in the United States and Europe. 
Approximately 18 subjects will be enrolled. 
 Inclusion Criteria (Section 4.1.1) 
Subjects are eligible for enrollment in the study if they meet all of the following inclusion 
criteria:  
1. The subject is ≥ 6 to < 12 years of age with body weight of ≥ 30 kg at the time of 
informed consent signing. 
2. The subject has a body we ight within the 5th through 95th percentile by age, inclusive, 
as determined by the National Center fo r Health Statistics ( Section  13.6). 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 95 3. The subject must have a diagnosis of GERD prior to randomization and medical 
history of signs or symptoms of GERD for at least 3 months prior to screening, based 
on physical examination, current symptoms (eg, heartburn),  or diagnostic tests (eg, 
pH or endoscopy). Notes in the medical records and/or other source documents, such as prior endoscopies, can be used to support the diagnosis and will be recorded in the 
electronic case report form (eCRF).  
4. The subject has at least  one moderate GERD symptom based on the GERD Symptom 
Assessment -Investigator scale performed at screening.  
5. The subject must be able to swallow study drug tablet with water. 
6. Parent or legal guardian (ie, legally authorized representative [LAR]) is willing and 
able to complete the informed consent process and subjects are able to comply with study procedures and visit schedule. 
7. Female subjects who have experienced menarche must have a negative pregnancy test 
and will be counseled on pregnancy avoidance (Section 13.2).   
 
Exclusion Criteria (Section 4.1.2) 
Subjects are not eligible for study participation if they meet any of the following exclusion 
criteria:  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 96 1. The subject has used prescription or non-prescription PPIs or H 2RAs within 7 days 
prior to randomization or requires use during the Treatment Period.  
2. The subject has used sucralfate, or antacids within 1 day prior to randomization or 
requires their use during the Treatment Period.  
3. The subject has received other agent s affecting digestive organs, including muscarinic 
antagonists (eg, hyoscyamine), prokinetics, oral anticholinergic agents, prostaglandins, bismuth from 30 days prior to Day 1 or requires their use during the course of the study. 
4. The subject has received atazanavir sulfate or rilpivarine  r
 ilpivirine  hydrochloride 
from 5 days prior to Day 1 or requires their use during the course of the study.  
5. The subject has received any investigational compound (including vonoprazan) wi
thin 30 days prior to the start of t he Screening Period. 
6. The subject is an immediate family member or is in a dependent relationship with a 
study site employee who is involved in the conduct of this study (eg, child, sibling) or 
subject may have consented under duress. 
7. The subject requires h ospitalization or has surgery scheduled during the course of the 
study or has undergone major surgical procedures within 30 days prior to the Screening Period. 
8. The subject has undergone prior gastrointestinal surgeries. 
9. The subject has any abnormal laborat or
 y test values that are considered clinically 
significant at in the start opinion of  the investigator during the Screening Period. 
10. The subject has a history of hypersensitivity or allergies to vonoprazan (including the formulation excipients:  D-mannitol, microcrystalline cellulose, hydroxypropyl 
cellulose, fumaric acid,  ascorbic acid,  croscarmellose sodium, magnesium stearate, 
hypermellose hypromellose , macrogol 8000, and titanium dioxide, or red or yellow 
ferric oxide) . 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 97 11. The subject has used any prescription or over-the-counter medications (including 
CYP3A4 inducers), including herbal or nutritional supplements ), other than those 
already excluded in criteria 1 to 5 above, within 14 days (or 5 half- lives)  before the 
first d ose of study drug or throughout the study. NOTE: Acid suppressive therapies 
are considered separately under exclusion criteria 1 and 2. That is, unless the 
medication(s) is permitted by the sponsor following a review of available data which 
confirms concomi tant administration of the medication is unlikely to affect either the 
safety of the patient or the pharmacokinetics of vonoprazan. 
12. The subject has consumed grapefruit or grapefruit juice, Seville orange or Seville 
ora
nge-containing products (eg, marmalade), or other food products that may be 
CYP3A4 inhibitors (eg, vegetables from the mustard green family [kale, broccoli, 
watercress, collard greens, kohlrabi, Brussels sprouts, mustard] and charbroiled meats) within 7 days (or 5 half- lives) before the first dose of study drug or throughout 
the study. 
13. The subject has positive results at screening for human immunodeficiency virus, hepatitis B virus, or hepatitis C virus (HCV) infection at screening. 
14. The subject has severe renal impairment (estimated glomerular filtration rate < 30 mL/min).  
15. The subject has moderate to severe hepatic impairment (Child -Pugh Class B and 
Child -Pugh Class C). 
16. The subject has any of the following abnormal laboratory test values at the start of the Screening Period: 
a. Creatinine levels: > 2 mg/dL (>177 μ mol/L).  
b. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2  × the 
upper limit of normal (ULN) or total bilirubin >2 × ULN (except subjects with Gilbert Syndrome). 
17. In the opinion of the investigator, the subject is not suitable for entry into the study. 
 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 98 Replacements (Section 4.2.4) 
Discontinued or withdrawn subjects will not be replaced. 
At the discretion of the sponsor, subjects may be replaced to achieve the target of 
approximately 18 subjects with expected usable pharmacokinetic sample collections.  
 
Treatments Administered (Section 5.2)  
Subjects will be administered study drug orally at the clinic on Day 1 and on Days 7 and 14, 
after the pre-dose pharmacokinetic sample, with approximately 240 mL (8 oz) of water in the 
morning between 7 and 10 am preferably prior to eating any breakfast or food. If necessary, a dosing cup can be used to facilitate administration. Study drug will be dispensed to the parent/LAR for study drug to be administered to the subject at home. Clinic staff will provide 
the parent/LAR a Study Drug Reminder Card and instruct the parent/LAR to record the date 
and time of every dose taken at home and to bring this card back to the next clinic visit.  
On Days 2 to 6 and 8 to 13, the parent/LAR  Pare
 nts/caregivers will be instructed to havegive 
the subject take randomized study drug orally with approximately 240 mL (8 oz) of water  
each morning between 7 and 10 am on an empty stomach with approximately 240 mL (8 oz) 
water.  Subjects will take study drug at the clinic on Days 1, 7, and 14; otherwise, study drug 
will be taken on an outpatient basis.preferably prior to eating any breakfast or food. Any 
missed doses should also  be notedrecorded by the parents/caregivers parent/LAR  and 
communicated to clinic staff  to record immediately. All dosing information including missed 
doses will be recorded on the Study Drug Reminder C ard and  in the eCRF.  
For the Days 6 and 13 dose, parents/caregivers will note the time it was taken by the subject. 
Clinic staff will record this information in the eCRF.  
Water is permitted as desired, except for 1 hour before and 1 hour after administration (other 
than what is permitted for study drug dosing). Subjects will be provided a On Days 7 and 14 
subjects may have a meal /snack  30 to 60 minutes after study drug dosing per the clinic’s . 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 99 Following completion of study drug dosing on Day 14 or early discontinuation, the subject 
will be transitioned to local standard  procedures of care for 14 days. Note, the local standard 
of care does not include study drug but can include other acid suppressant agents.  
Identity of Investigational Product (Section 5.3)  V onoprazan study medication will be supplied as 10 mg and 20 mg tablets.  
 manuf
actures 
the vonoprazan fumarate drug substance.  
 manuf
actures the vonoprazan tablets. 
V onoprazan tablets contain vonoprazan free base (MW 345.39) and the following inactive 
excip
ients: D -Mannitol, microcrystalline cellulose, hydroxypropyl cellulose, fumaric acid, 
ascorbic acid, croscarmellose sodium, magnesium stearate, hypromellose, polyethylene 
glycol 8000, titanium dioxide, and red or yellow ferric oxide. 
Study drug will be packaged in bottles for shipment t o the in vestigational site.  
 Study Drug Packaging and Storage (Section 5.4.1)  V onoprazan tablets will be packaged in bottles  and shi
 pped by . 
Study supplies must be stored in a secure area (eg, a locked cabinet), protected from 
moisture, and kept at a controlled room temperature (20°C to 25°C [68°F to 77°F]; excursions are allowed between 15°C and 30°C [59°F to 86°F]) until they are used or returned to the sponsor or designee for destruction. Study drug must be stored under the 
conditions specified on the label and remain in the original container until dispensed. 
Sites should refer to the pharmacy manual for detailed information regarding packaging and 
labeling and for reporting temperature excursions. 
 
Treatment Compliance (Section 5.7.1) 

Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 100 Compliance wi th study drug is to be assessed as specified in the SoE (Section 13.1). 
Compliance with study drug dosing will be assessed by clinic staff reviewing the Study Drug 
Reminder Card returned at each visit, direct questioning and counting any returned capsules tablets , which will be documented in the source documents and eCRF.  
A record of the number of study drug tablets dispensed to and taken by each subject must be 
maintained and reconciled with study drug and compliance records. Study drug start and stop 
dates will also be recorded in the eCRF. 
If the subjects exhibit The date and time of each dose taken (in clinic or at home) must be 
recorded on the Study Drug Reminder Card, source documents and eCRF. If a subject misses 
any dose for any reason, the sponsor must be notified immediately, and the date of the missed 
dose(s) and reason must be recorded in the eCRF.   
If a subject misses a scheduled visit or exhibits  poor c ompliance, as assessed by capsuletablet  
counts, the sponsor should be notified immedi ately to determine appropriate mitigation. 
Actions may include subjects provided with specific dosing instructions to continue study 
drug or discontinuation from the study. The  LARs and subjects should be counseled at each 
visit on the importance of good compliance with regarding the study dosing regimen and 
scheduled study visits . 
 
Pri
or and Concomitant Therapy (Section 5.8) 
Any medication or vaccine (including over- the-counter or prescription medicines, vitamins, 
and/or herbal supplements) that the subject  is receiving at the time of screening (or has 
received within 30 days before the time of screening) or receives during the study must be 
recorded along with the following: 
• Reason for use 
• Dates of administration, including start and end dates 
• Dosage information, including dose and frequency 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 101 The LARs and subjects are to be instructed that the subject should not take any medications, 
including over-the-counter medications, without first consulting the investigator or 
subinvestigators. However, single-use medications for endoscopic examination and topical medications, including liniments, ophthalmic drops, nasal drops, ear drops, inhaled drugs, adhesive skin patches, and gargle (mouthwash) will be allowed, whether or not they are 
excluded or restricted.  
Prior use of H
2RAs or PPIs should be documented. The dose and duration and whether or not 
symptoms were relieved by the medication will be collected.  
The medical monitor should be contacted if there are any questions regarding prior or concomitant therapy. 
 Excluded Medications (Section 5.8.1) A list of excluded medications is provided in Tab
 le 5-
1 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 102 Table 5-1 Excluded Medications and Treatments  
Excluded Medications and Treatments  Beginning of 
Exclusion End of Exclusion  
Other investigational drugs or drugs administered due 
to participation in another clinical trial  30 days prior to start of 
Screening Period Follow -up  
phone call 
Antacids and sucralfate  Day - 1 (day before first 
dose of study drug) Day 14 (end of 
study drug 
dosing) 
H2RAs 7 days prior to Day -1 Day 14 (end of study drug dosing) 
PPIs 7 days prior to Day -1 Day 14 (end of 
study drug 
dosing) 
Strong inhibitors or inducers of CYP3A4 
(eg, itraconazole, ketoconazole, indinavir, nelfinavir, 
ritonavir, saquinavir, telithromycin)  14 days prior to Day 1  End of treatment  
Day 14 (end of 
study drug 
dosing)  
CYP3A4 substrates with a narrow therapeutic index  14 days prior to Day 1  End of treatment  
Day 14 (end of 
study drug dosing)  
CYP2C19 substrates clopidogrel, citalopram, 
cilostazol  14 days prior to Day 1  End of treatment  
Day 14 (end of study drug 
dosing)  
Other agents affecting digestive organs, including 
muscarinic antagonists (eg, hyoscyamine), 
prokinetics, oral anticholinergic agents, prostaglandins, bismuth  30 days prior to Day 1  Follow-up  phone call 
Atazanavir sulfates; rilpivirine hydrochloride 
(contraindicated with vonoprazan)  5 days prior to Day 1 Follow-up  
phone call  
CYP: cytochrome P450 isoenzyme; H 2RA: histamine -2 receptor antagonist; PPI: proton pump inhibitor  
 
Pharmacokinetic Assessments (Section 6.1.1) 
Parents/caregivers will be asked to note the exact time the subject took their study drug dose 
on Days 6 and 13. Clinic staff will record this information in the eCRF. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 103 Parents/caregivers Parents/LARs  will ensure that the subject arrives at the clinic in the 
morning on Days 7 and 14 for pharmacokinetic sampling. Subjects should not eat or take the 
vonoprazan study medication drug before arriving  toat the clinic. Subjects The Day 7 and 14 
dose of study drug will be  released from given in the clinic  after pharmacokinetic sampling 
and study procedures are completed.   
Blood samples for pharmacokinetic analysis of vonoprazan in plasma will be collected on Days 7 and 14. On each o f this days On Day 7, one pre- dose sample will be collected prior to 
the morning administration of vonoprazan along with two additional samples collected after drug administration: one between 0.5 to 1.5 hours post-dose and one between 2.5 to 3.5 hours 
post-dose. On Day 14, one pre-dose sample will be collected prior to the morning 
administration of vonoprazan. Two  along with two additional samples  will be collected after 
drug administration: one between 0.5 and1 to 2 hours post-dose and one between 2.5 and 3 to 
4 hours post- dose. The exact date and  time of each pharmacokinetic sample must be recorded 
in subject source document and eCRF . 
If a subject terminates early, an attempt should be recor ded.made to collect one blood sample 
if it can be collected within  24 hours following the last dose of study drug. The exact date 
and time of the early termination sample must be recorded.  
Samples Blood samples  will b e collected into  appropriate bloodsodium heparin vacutainer 
collection tubes, as specified by the bioanalytical laboratory and processed into plasma . 
Details of collection, processing, storage and shipping will be contained in the Clinical 
Laboratory Manual. 
Bioanalytical Methods Plasma concentrations of vonoprazan will be measured at Labcorp Early Development 
Labor
atories Inc. (Madison, WI) using a validated liquid chromatrography/mass spectrometry 
method with an analytical range of 10.5 to 100 µg ng/mL and will be used for the calculation 
of the plasma vonoprazan pharmacokinetic p arameters.  
Depending on pace of enrollment, pharmacokinetic samples from a subset or subsets of subje
cts may be analyzed prior to the completion of enrollment. In any case, all of the 
pharmacokinetic samples collected from a given subject will be analyzed in the same bioanalytical batch.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 104 Pharmacokinetic Parameters  
Plasma pharmacokinetic parameters shown in Table  6-1 will be estimated using a non -lin ear 
mixed effects model and will be determined from the concentration- time data for all 
evaluable subjects. The primary vonoprazan pharmacokinetic endpoints will include the 
following steady state parameters: C max,ss, AUC τ, CL/F and V z/F. Actual sampling times, 
rather than scheduled or nominal sampling times, will be used in all computations using 
sampling time. A dditional pharmacokinetic parameters may be estimated as appropriate.  
Table 6-1 Pharmacokinetic Parameters to be Estimated using Vonoprazan Plasma 
Concentration Data 
Parameter  Definition  
Cmax,ss Maximum observed plasma concentration at steady state 
Cmax,ss/Dose  Dose -normalized C max,ss (Cmax,ss divided by the administered dose in mg)  
AUC τ,ss Area under the plasma concentration -time curve during the dosing interval τ, where τ  is 
the length of the dosing interval in hours, calculated using the linear tr apezoidal rule  
AUC τ,ss/Dose  Dose -normalized AUC τ,ss (AUC τ,ss divided by the administered dose in mg) 
λz Terminal elimination rate constant, calculated as the negative slope of the log -linear 
regression of the natural logarithm concentration -time curve during the terminal phase  
CL/F  Apparent total plasma clearance after oral (extravascular) administration, calculated as 
Dose/ AUC τ,ss 
Vz/F Apparent volume of distribution during the terminal elimination phase after oral (extravascular) administration, calculated as (CL/F)/ λ
z 
 
Pharmacodynamic Assessments (Section 6.1.2) 
IfSelect sites may participate in a sub -study c ollecting gastric pH when deemed clinically 
indicated necessary  by the principal investigator. In the pharmacodynamic sub-study, gastric 
pH will be measured and recorded continuously for a 24-hour period on scheduled days Day -
1 and Day 7 as outlined in the SoE ( Section  13.1) using a suitable pH probe and ambulatory 
pH rec
ording system . All instruments will be calibrated prior to and following use. Gastric 
pH will be sampled and recorded every 5 seconds. The 24-hour continuous pH recording 
session for Day - 1 will commence 24 -hours prior to the first dose of study drug. The 24-hour 
continuous pH recording session for Day 7 will commence 30 to 60 minutes prior to  
treatment administration  the next dose of study drug. Th e reason for pH assessments, start 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 105 time, stop time and any interruptions will be recorded in the source document and the case 
report form (CRF) eCRF. To minimize the discomfort of probe insertion, administration of a 
topical anesthetic (lidocaine) will be permitted . After each 24 -hour period, per the 
flashcard institutional process. Details of collection, processing, storage and shipping will be 
removed from contained in the recorder and  the Gastric pH data will be transferred to the 
computer.Monitoring Plan.  
 
Gerd Symptom Assessment -Investigator (Section 6.2.1) 
The GERD Symptom Assessment-Investigator scale evaluates 4 symptoms of GERD: 
hear
tburn, vomiting, acid regurgitation, and trouble eating. The maximum severity of each 
GERD symptom occurring during the 7 days prior to the study visit , Day 7 and Day 14 will 
be assessed. The severity for each symptom will be recorded as either none, mild, moderate, 
severe or very severe. At screening, the subject will be eligible for inclusion in the study if 
the subject has at least one moderate GERD symptom. Symptom and severity definitions are presented in Section  13.4.1. 
A
dverse Events of Special Interest (Section 6.3.1.1.4) 
An AE of special interest is a notewor thy event for the particular product or class of products 
that a sponsor may wish to monitor carefully. It could be serious or nonserious (eg, hair loss, loss of taste, impotence), and could include events that might be potential precursors or prodromes for more serious medical conditions in susceptible individuals. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 106 Adverse events of special interest include any event listed in Table  6-23. 
Table 6-23 Adverse Events of Special Interest List  
Term  
Hepatotoxicity  
Severe cutaneous adverse reactions, including hypersensitivity 
Clostridium difficile  infections and pseudomembranous colitis 
Hypersensitivity reactions (anaphylaxis)  Acute interstitial nephritis/tubulointerstitial nephritis   
Bone fracture Hematologic abnormalities  
 
For additional details on liver function monitoring, see Section 13.2. Safety Reporting to Investigators, IRB/IECs, and Regulatory Authorities (Section 6.3.1.3.4) 
The sponsor designee (contract research organization) will be delegated the responsibility for 
reporting all suspected unexpected serious adverse reactions (SUSARs) and any other applicable SAEs to regulatory authorities, investigators, and the IRB/IEC, as applicable. Relative to the first awareness of the event by/or further provision to the sponsor or sponsor’s 
designee, SUSARs will be submitted to the regulatory authorities (eg , EudraVigilance 
Database, FDA Adverse Event Reporting System)  as an expedited  report within 7 days for 
fatal and life -threatening events and 15 days for other serious events, unless otherwise 
required. The sponsor designee will also prepare an expedited report for other safety issues that might materially alter the current benefit- risk assessment of an investigational medicinal 
product or that would be sufficient to consider changes in the investigational medicinal 
products. 
Laboratory Analyses (Section 6.3.3) 
See Table  6-4 for the list of clinical laboratory tests to be performed and the SoE 
(Section  13.1) for the timing and frequency. 
• The investigator must review the laboratory report, document this review, and record 
any clinicall y relevant changes occurring during the study in the AE section of the 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 107 eCRF. The laboratory reports must be filed with the source documents. Abnormal 
laboratory findings that are expected with the underlying disease should not be 
considered clinically significant unless judged by the investigator to be more severe than expected for the subject’s condition. 
• All laboratory tests with abnormal values considered clinically significant during 
participation in the study or within 30 days after the last dose of st udy drug should be 
repeated until the values return to normal or baseline or are no longer considered 
clinically significant by the investigator or medical monitor.  
o If such values do not return to normal/baseline within a period of time judged 
reasonable by the investigator, the etiology should be identified, and the 
sponsor notified. 
o All protocol-required laboratory assessments, as defined in Table  6-34 , must 
be conducted in accordance with the laboratory manual and the SoE. 
 If laboratory values from non–protocol-specified laboratory as
sessments performed at the institution’s local laboratory require a 
change in subject management or are consid ered clinically significant 
by the investigator (eg, SAE, AE, or dose modification), then the 
results must be recorded in the unscheduled laboratory eCRF. 
All samples will be collected in accordance with acceptable laboratory procedures. Details of 
these p rocedures and required safety monitoring will be provided in the laboratory manual. 
All study -required laboratory assessments will be performed by a central laboratory. 
 
  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 108 Table 6- 4 Protocol- Required Safety Laboratory Assessments  
Laboratory 
Assessments  Parameters  
Hematology  • Platelet count 
• RBC count  
• Hemoglobin  
• Hematocrit  
• RBC indices: MCV, MCH  
• Percent reticulocytes  
• WBC count with differential: neutrophils, lymphocytes, monocytes, eosinophils, 
basophils  
Clinical chemistry a • Blood urea nitrogen  
• Creatinine  
• Total and direct bilirubin  
• ALT/SGPT  
• AST/SGOT  
• Alkaline phosphatase  • Total protein  
• Potassium  
• Sodium  
• Calcium  
• Glucose  b  
• GGT  
Routine urinalysis c  • Specific gravity, appearance, color  
• pH, glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocyte 
esterase  
• Microscopic examination (if blood or protein is abnormal)  
Other screening tests  • Serology (HIV antibody, HBsAg, and HCV  antibody, hepatitis C,  HCV  viral 
load RNA [qualitative]),  hCG pregnancy test d  
ALT:  alanine aminotransferase; AST:  aspartate aminotransferase; GGT:  gamma -glutamyl transferase; 
HBsAg: hepatitis B surface antigen; HCV: hepatitis C virus; HIV:  human immunodeficiency virus; 
MCH:  mean corpuscular hemoglobin; MCV:  mean corpuscular volume; RBC: red blood cell; 
RNA:  ribonucleic acid; SGOT: serum glutamic -oxaloacetic transaminase; SGPT: serum glutamic- pyruvic 
transaminase; WBC:  white blood cell  
a See Section  13.2  13.3 for the appropriate guidance on reporting of abnormal liver function tests. For 
liver function test monitoring, see Section  13.2.1 13.3.1  For temporary and permanent discontinuation of 
study drugs  due to abnormal liver function tests, see Section  13.2.2 and Section 12.2.3  13.3. 2 and 
Section  13.3.3 , respectively.  
b Glucose will be obtained after an 8- hour f ast at Visit 1 and at any unscheduled visit.  
c At the discretion of the investigator.  
d Only female subjects who have experienced menarche will have urine hCG; if the urine hCG test is 
positive confirm with serum hCG.  
 
Investigators must document their review of each laboratory safety report. 
 
 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 109 Physical Examinations (Section 6.3.4) 
Refer to the SoE (Section  13.1) for the timing and frequency for full and brief physical 
examinations, as well as height and body weight.  
A complete  phys ical examination will include, at a minimum, assessments of the skin, 
cardiovascular, respiratory, gastrointestinal, and neurological systems and Tanner staging 
(Section  13.5).  Height and body weight will also be measured and recorded. 
A brie
f physical examination will include, at a minimum, assessments of the skin, 
cardiovascular, respiratory, and gastrointestinal systems. Investigators should pay special attention to clinical signs related to previous serious 
illnesses.  
 
Electrocardiograms (Section 6.3.6) Refer to the SoE (Section  13.1) for the timing and frequency of ECG assessments.  
A single, standard 12- lead E
 CG recording will be made after  the subject has been in the 
supine position for at least 5 minutes. ECGs will be read and interpreted centrally by a 
pediatric cardiologist for eligibility during Screening and on Day 14.  A single repeat 
measurement is permitted  at during screening period for eligibility determination. 
Measurements of the following intervals will be reported: PR interval, RR interval, QT 
interval, and QRS interval. The QT interval adjusted for heart rate will be derived in the 
electronic database from the RR and QT i ntervals, using the Fridericia method. Assessments 
should will include comments on whether the tracings are normal or abnormal (if abnormal, 
whether clinically significant or not clinically significant) ; rhythm; the presence of 
arrhythmia or conduction defects; any evidence of myocardial infarction; and ST-segment, 
T wave, and U wave abnormalities . 
 
  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 110 Statistical and Analytical Plan (Section 7) 
This section describes the statistical and analytical methods to be used for the study. A 
statistical analysis plan will provide further details of the statistical methods for the analysis.  
 
Sample Size Calculations (Section 7.1) 
Approximately 18 subjects are expected to be enrolled with 9 subjects in each dose group. 
Attempts will be made to enroll subjects across the ≥ 6 to < 12 years age range. Because this is a pharmacokinetic and safety trial with no comparator, there is no power determination affecting the sample size. The sample size of approximately 18 subjects is considered 
sufficien t to assess the pharmacokinetics, safety, and tolerability of vonoprazan in this 
population. Fewer subjects may be enrolled based on preliminary data, if considered 
sufficient to adequately characterize the PK profile.  
 
Analysis Sets (Section 7.2) 
The pharmacokinetic population will include subjects who receive at least 1 dose of study 
drug and have sufficient concentration data to support accurate estimation of at least 1 
pharmacokinetic parameter.  
The pharmacodynamic population will include subjects who receive at least 1 dose of study 
drug and have sufficient pH data to support calculation of pharmacodynamic parameters. 
The safety population will include all subjects who receive at least 1 dose of study drug.  
 
Pharmacokinetic Analyses (Section 7.3.1)  The individual pharmacokinetic parameter estimates in Tab
 le 
6-1 will be summarized 
desc
riptively by vonoprazan dose. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 111 The following pharmacokinetic parameters will be considered the primary endpoints for the 
study: C max,ss, AUC τ, CL/F, V z/F. 
 
Pharmacodynamic Analyses (Section 7.3.2) 
Mean pH and the percentage of time above pH 4, 5, and 6 at baseline (Day -1) and Day 7 will 
be summarized for the subset of subjects for whom intragastric pH monitoring is available. 
 Efficacy Analyses (Section 7.3.3) The severity of GERD symptoms at baseline and Days 7 and 14, as assessed by the 
investigator, will be summarized overall and by vonoprazan dose. 
 Interim Analyses (Section 7.3.5) No formal interim analyses will be performed in this study.  
However, a popPK analysis of interim data from a subset of subjects may be conducted prior 
to completion of enrollment to assess whether plasma exposure in pediatric subjects aged ≥ 6 to < 12 years is within the range observed in adults receiving the same dose.  
 
Data Quality Assurance (Section 8) This study will be conducted according to the International Council for Harmonisation (ICH) 
E6(R
2) risk and quality processes described in the applicable procedural documents and 
Regulation 536/2014 of the European Parliament and of the council of 16 April 2014 on clinical trials on medicinal products for human use and repealing Directive 2001/20/EC. The 
quality management approach to be implemented in this study will be documented and will comply with the current ICH guidance on quality and risk management [ DHHS
 2018]. The 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 112 sponsor assumes accountability for actions delegated to other individuals (eg, contract 
research organizations).  
 
Ethical Conduct of the Study (Section 9.2)   
The study will be performed in accordance with the ethical principles that have their origin in 
the Declaration of Helsinki, ICH GCP, the protocol, and all applicable regulations. 
All potential serious breaches must be reported to the sponsor or designee immediately. A 
serious breach is a breach of the conditions and principles of GCP in connection with the study or the protocol which is likely to affect to a significant degree the safety or physical or 
mental integrity of the subjects of the study or the scientific value of the study. 
 Investigator’ s Obligations (Section 10) The following administrative items are meant to guide the investigator in the conduct of the 
study but may be subject to change based on industry and government standard operating 
procedures, working practice documents, or guidelines. Changes will be reported to the IRB/IEC but will not result in protocol amendments.  
The Investigator will also be responsible for providing oversight of the conduct of the study or site, including oversight of all personnel involved in the study, and adherence to all applicable laws and regulations as set forth in the Clinical Trial Agreement.  
Personnel involved in conducting this study will be qualified by education, training and 
experience prior to performing their respective tasks.  
 
External Data Monitoring Committee (Section 11.1.1) An external data monitoring committee will not be used for this study. This is a Phase 1 study 
with 14 days dosing and adverse events will be evaluated on an ongoing basis. Additionally, 
vonoprazan has a well characterized safety profile in adults.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 113 Final Report (Section 11.4) 
Whether the study is completed or prematurely terminated, the sponsor will ensure that the 
clinical study reports are prepared and provided to the regulatory agency(ies) as required by the applicable regulatory requirement(s). The sponsor will also ensure that the clinical study reports in marketing applications meet the standards of the ICH harmonised tripartite 
guideline E3: Structure and content of clinical study reports.  
Where required by applicable regulatory requirements, an investigator signatory will be 
identified for the approval of the clinical study report. The investigator will be provided reasonable access to statistical tables, figures, and relevant reports and will have the 
opportunity to review the complete study results. 
The study results will be posted on publicly available clinical trial registers. The s
 ponsor will 
submit to clinical trial registries a summary of the results of the clinical trial and where 
applicable a summary that is  understandable to a layperson, and the clinical study report 
health authorities, within 6 months after the end of the study. The investigator is encouraged 
to share the summary results with the LARs and study subjects, as appropriate.  
 
  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 115 a For subjects participating in the pharmacodynamic substudy, Visit 2 (Day -1) and Visit 56 (Day 8)  are only required for 
subjects undergoing gastric pH monitoring if clinically indicated at select sites. pH monitoring will be conducted on 
Day -1 for 24 hours and on Day 7 for 24 hours. pH probes would be placed on Days -1 and 7 and removed on Days 1 
and 8. 
b At an unscheduled visit, the following procedures are to be completed with additional procedures at the investigator’s 
dis
cretion: a brief physical examination, vital sign measurements, concomitant medication assessment, AE assessment, 
and clinical laborator y tests. If the visit results in premature termination, then all procedures outlined for the final visit 
should be performed.  
c Informed consent will be signed by the subject’s legally authorized representative prior to any activity in the study. Subject assent (if applicable) may be obtained as required per site guidelines.  
d A complete physical examination will be performed at screening (at minimum, assessment of skin, cardiovascular, res
piratory, gastrointestinal, and neurological systems and Tanner stag ing). A brief physical examination will be 
performed at other visits (at minimum, assessment of skin, cardiovascular, respiratory, and gastrointestinal systems). Interim physical examinations may be performed at the discretion of the investigator, if necessary, to evaluate AEs or clinical laboratory abnormalities.  
e Vital signs will include systolic and diastolic blood pressure, pulse rate, respiratory rate, and temperature.  
f Heig
ht collected only at screening.  
g Hepatitis B surface antigen, hepatitis C virus antibody, and HIV type 1 and 2 antibodies.  
h Clinical laboratory testing will include hematology, serum chemistry, and urinalysis (if deemed necessary by the PI). Blood draws should follow vital signs or electrocardiograms.  
i Only female-born subjects , Tan
 ner stage 2 development  who have reached menarche, will require guidance on 
avoidance of pregnancy and urine or serum  hCG; if urine hCG is  positive, confirm with serum hCG.  
j Single 12 -lead  el ectrocardiogram recordings will be made after the subject h as been in the supine position for at least 5 
minutes at screening. A pediatric cardiologist will interpret the ECG for eligibility and any abnormality.  A single repeat 
measurement is permitted at screening for eligibility determination Measurements of the following intervals will be 
reported: PR interval, RR interval, QRS interval, and QT interval. The QT interval adjusted for heart rate will be 
derived in the electronic database from the RR and QT intervals, using the Fridericia method. after the read by a 
pediatric cardiologist.  Assessments should include comments on whether the tracings are normal or abnormal (if 
abnormal, whether clinically significant or not clinically significant); rhythm; the presence of arrhythmia or conduction 
defects; any evidence of myocardial infarction; and ST segment, T wave, and U wave abnormalities.  An ECG will be 
collected at the final visit and interpreted by a pediatric cardiologist.  
k Subject will be randomized to study treatment after all eligibility criteria have been met.  
l Stud
y drug will be administered in the clinic on Days  1, 7, and 14. On Days 7 and 14, subjects will be provided a meal 
3060 minutes after study drug dosing per the clinic’s standard procedures.  Study drug should be taken every day 
between 7 and 10 am preferably prior to eating any breakfast or food. Study drug for at home administration will be dispensed on Day 1 (to be taken on Days 2 to 6) and Day 7 (to be taken on Days 8 to 13). At home, parents/caregivers 
will administer study drug to subjects. Study drug should be taken every day between 7 and 10 am.  Clinic staff will 
review instructions with parents/LARs for administering study drug at home and completing the Study Drug Reminder 
Card. Phone call reminders may be conducted as required.  
m Gastric pH monitoring on Day 1 for 24 hours and on Day 7 for 24 hours; only if clinically indicated. pH probes would 
be placed on Days 1 and 7 and removed on Days 1 and 8. Blood samples for PK analysis of vonoprazan in plasma will 
be collected on Days 7 and 14. On bothOn Day 7 days, one pre -dose sample will be collected prior to the morning 
administration of vonoprazan along with two additional samples collected after drug administration: one between 0.5 to 1.5 hours post -dose and one between 2.5 to 3.5 hours post -dose. On Day 14 days, one pre -dose sample will be collected 
prior to the morning administration of vonoprazan and along with  two additional samples will be collected after drug 
administration: one b etween 0.51 to 2 hours post -dose and one between 2.5 and 3 to 4 hours post -dose. The exact time 
of each pharmacokinetic sample should be recorded in the source and eCRF.   
If a subject terminates early, an attempt should be made to collect one blood sample if it can be collected within 24 hours following the last dose of study drug. The exact date and time of the early termination sample must be recorded.  
n Collection of pretreatment events will start after the informed consent form has been signed. Adverse events will be ass
essed from time of informed consent signing until the follow -up visit and should be followed until they are resolved, 
stable, or judged by the investigator to be not clinically significant.  
   
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 116 Appendix 2: Contraceptive Guidance  (Section 13.2) 
Contraception Guidance: 
From  signing of informed  consent, throughout the duration of the study, and for 2 weeks  after 
the last dose of study drug, female subjects  of childbearing potential*  who are sexually  active 
with a nonsterilized male partner** must use adequate contraception. In addition, they must 
be advised not to donate ova during this period. 
*Females NOT of childbearing potential are defined as those who are premenarchal, 
have been surgically sterilized (hysterectomy, bilateral oophorectomy, or tubal ligation) or who are postmenopausal (eg, defined as at least 1 year since last regular 
menses with a follicle -stimulating hormone level >40 International units per liter  or at 
least 5 years since last regular menses,  confirmed before any study drug is 
implemented).  
**Sterilized males should be at least 1 -year post vasectomy and should have 
confirmed that they have obtained documentation of the absence of sperm in the 
ejaculate.  
Note: If the childbearing potential of a subject changes after start of the study (eg, a 
premenarchal female subject experiences menarche) or the risk of pregnancy changes (eg, a 
female subject who is not heterosexually active becomes active), the participant must discuss this with the investiga tor, who should determine if the female subject must begin a highly 
effective method of contraception or a male participant must use a condom. 
Birth Control: Birth control methods considered acceptable for this study include: 
Barrier methods (each time that you have intercourse) : 
• Male condom PLUS spermicide 
• Cap (plus spermicidal cream or jelly) PLUS male condom and spermicide 
• Diaphragm (plus spermicidal cream or jelly) PLUS male condom and spermicide  
Intrauterine Devices  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 117 • Copper T PLUS condom or spermicide  
• Progesterone T PLUS condom or spermicide 
Hormonal Contraceptives 
• Implants  
• Hormone shot/injection 
• Combined pill 
• Minipill  
• Patch  
• Vaginal ring PLUS male condom and spermicide 
During the course of the study, serum human chorionic gonadotropin ( hCG)  will be 
performed at screening and regular urine hCG pregnancy tests will be performed only for 
women of childbearing potential. Subjects will receive continued guidance with respect to the avoidance of pregnancy as part of the study procedures (Section 13.1) . Female subjects 
must have a negative urine hCG pregnancy test on Day -1 prior to study drug dispensation. 
 
  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 118 Appendix 5: Tanner Staging (Section 13.5) 
Tanner Staging will be reported based on the following criteria:  
 
   

Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 119 Appendix 6: National Center for Health Statistics Clinical Body Weight Charts with 5th and 
95th Percentiles  (Section 13.6)  
13.6.1 Girls  
 

Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 120 13.6.2 Boys  
 

Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 121 13.7.2  Protocol Amendment 2 
Exclusion Criteria (Section 4.1.2) 
Subjects are not eligible for study participation if they meet any of the following exclusion 
criteria:  
1. The subject has used prescription or non-prescription PPIs or H 2RAs within 7 days 
prior to randomization or requires use during the Treatment Period.  
2. The subject has used sucralfate, or antacids within 1 day prior to randomization or requires their use during the Treatment Period.  
3. The subject has received other agents affecting digestive organs, including muscarinic 
antagonists (eg, hyoscyamine), prokinetics, oral anticholinergic agents, 
prostaglandins, bismuth from 30 days prior to Day 1 or requires their use during the course of the study. 
4. The subject has received atazanavir sulfate or rilpiv irine hydrochloride from 5 days 
prior to Day 1 or requires their use during the course of the study.  
5. The subject has received any investigational compound (including vonoprazan) within 30 days prior to the start of the Screening Period. 
6. The subject is an immediate family member or is in a dependent relationship with a study site employee who is involved in the conduct of this study (eg, child, sibling) or subject may have consented under duress. 
7. The subject requires hospitalization or has surgery scheduled during the course of the 
study or has undergone major surgical procedures within 30 days prior to the 
Screening Period. 
8. The subject has undergone prior gastrointestinal surgeries. 
9. The subject has any abnormal laboratory test values that are considered clinically 
significant in the opinion of the investigator during the Screening Period. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 122 10. The subject h as a history of hypersensitivity or allergies to vonoprazan (including the 
formulation excipients:  D-mannitol, microcrystalline cellulose, hydroxypropyl 
cellulose, fumaric acid, ascorbic acid, croscarmellose sodium, magnesium stearate, 
hypro mellose, macrog ol 8000, and titanium dioxide, or red or yellow ferric oxide). 
11. The subject has used any prescription or over-the-counter medications (including 
her
bal or nutritional supplements), other than those already excluded in criteria 1 to 5 
above, within 14 days before the first dose of study drug or throughout the study. That 
is, unless the medication(s) is permitted by the sponsor following a review of 
available data which confirms concomitant administration of the medication is 
unlikely to affect either the safety of the patient or the pharmacokinetics of 
vonoprazan. 
12. The subject has consumed grapefruit or grapefruit juice, Seville orange or Seville ora
nge-containing products (eg, marmalade), or other food products that may be 
CYP3A4 inhibitors (eg, vegetables from the mustard green family [kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard] and charbroiled meats) within 7 days (or 5 half-lives) before the first dose of study drug or throughout 
the study. 
13. The subject has positive results at screening for human immunodeficiency virus, 
hepatitis B virus, or hepatitis C virus (HCV) infection at screening. 
14. The subject has severe renal impairment (estimated glomerular filtration rate < 30 
mL/min).  
15. The subject has moderate to severe hepatic im pairment (Child -Pugh Class B and 
Child -Pugh Class C). 
16. The subject has any of the following abnormal laboratory test values at the start of the Screening Period: 
a. Creatinine levels: > 21
  mg/dL (>17788 μ mol/L).  
b. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2  × the 
upper limit of normal (ULN) or total bilirubin >2 × ULN (except subjects with Gilbert Syndrome). 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 123 17. In the opinion of the investigator, the subject is not suitable for entry into the study. 
Pregnancy (Section 3.3.2) 
If any subject is found to be pregnant during the study, she should be withdrawn, and any 
sponsor-
supplied drug (vonoprazan active) should be immediately discontinued. If the 
pregnancy occurs during administration of active study drug, eg, after Visit 2 or within 42 
weeks of the last dose of active study drug, the pregnancy should be reported immediately, using a pregnancy notification form, to the contact listed in Section 6.3.1.3.2. If the subject (and L
AR, if legally applicable) agrees to the primary care physician being informed, the 
investigator should notify the primary care physician that the subject was participating in a 
clinical study at the time she became pregnant and provide details of the treatment the subject 
received. All pregnancies will be reported u sing the pregnancy form and will be followed up 
to final outcome. The outcome, including any premature termination, must be reported to the sponsor. An evaluation after the birth of the child will also be conducted. 
Prior and Concomitant Therapy (Section 5.8) 
Any me
dication including H 2RAs and PPIs  or vaccines  (including over-the-counter or 
prescription medicines, vitamins, and/or herbal supplements) that the subject is receiving at 
the time of screening (or has received within 30 days before the time of screening) or 
receives during the study must be recorded along with the following: 
• Reason for use 
• Dates of administration, including start and end dates 
• Dosage information, including dose and frequency 
The LARs and subjects are to be instructed that the subject should not take any medications, 
including over-the-counter medications, without first consulting the investigator or 
subinvestigators. However, single-use medications for endoscopic examination and topical medications, including liniments, ophthalmic drops, nasal drops, ear drops, inhaled drugs, adhesive skin patches, and gargle (mouthwash) will be allowed, whether or not they are 
excluded or restricted.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 124 The medical monitor should be contacted if there are any questions regarding prior or 
concomitant t herapy.  
Laboratory Analy ses (Section 6.3.3) 
Investigators must document their review of each laboratory safety report. 
See Table  6-4 for the list of clinical laboratory tests to be performed and the SoE 
(Secti
on 13.1) f
or the timing and frequency. 
• The investigator must review the laboratory report, document this review, and record 
any clinically relevant changes occurring during the study in the AE section of the 
eCRF. The laboratory reports must be filed with the source documents. Abnormal 
laboratory findings that are expected with the underlying disease should not be 
considered clinically significant unless judged by the investigator t o be more severe 
than expected for the subject’s condition. 
• All laboratory tests with abnormal values considered clinically significant during 
participation in the study or within 30 days after the last dose of study drug should be repeated until the values return to normal or baseline or are no longer considered 
clinically significant by the investigator or medical monitor.  
o If such values do not return to normal/baseline within a period of time judged reasonable by the investigator, the etiology should be identified, and the 
sponsor notified. 
o All protocol-required laboratory assessments, as defined in Tab
 le 6-
4 must be 
conduct
ed in accordance with the laboratory manual and the SoE. 
 If la
boratory values from non–protocol-specified laboratory 
assessments perf ormed at the institution’s local laboratory require a 
change in subject management or are considered clinically significant 
by the investigator (eg, SAE, AE, or dose modification), then the 
results must be recorded in the unscheduled laboratory eCRF. 
All s amples will be collected in accordance with acceptable laboratory procedures. Details of 
these procedures and required safety monitoring will be provided in the laboratory manual. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 125 All study -required laboratory assessments will be performed by a central laboratory.  
Table 6-4 Protocol- Required Safety Laboratory Assessments  
Laboratory 
Assessments  Parameters  
Hematology  •Platelet count
•RBC count
•Hemoglobin
•Hematocrit
•RBC indices: MCV, MCH
•Percent reticulocytes
•WBC count with differential: neutrophils, lymphocytes, monocytes, eosinophils,basophils
Clinical chemistry a • Blood urea nitrogen  
•Creatinine
•Total and direct bilirubin
•ALT/SGPT
•AST/SGOT
•Alkaline phosphatase•Total protein
•Potassium
•Sodium
•Calcium
•Glucose  b
•GGT
Routine urinalysis c  •Specific gravity, appearance, color
•pH, glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocyteesterase
•Microscopic examination (if blood or protein is abnormal)
Other screening tests  • Serology (HIV antibody, HBsAg, HCV antibody, HCV viral load RNA [qualitative]), hCG pregnancy test 
d  
ALT:  alanine aminotransferase; AST:  aspartate aminotransferase; GGT:  gamma -glutamyl transferase; 
HBsAg: hepatitis B surface antigen; HCV: hepatitis C virus; HIV:  human immunodeficiency virus; hCG : 
human chorionic gonadotropin; MCH:  mean corpuscular hemoglobin; MCV:  mean corpuscular volume; 
RBC: red blood cell; RNA: ribonucleic acid; SGOT: serum glutamic -oxaloacetic transaminase; SGPT: ser um 
glutamic -pyruvic transaminase; WBC:  white blood cell  
a See Section  13.3 for the appropriate guidance on reporting of abnormal liver function tests. For liver 
function test monitoring, see Section  13.3.1. For temporary and permanent discontinuation of study 
drugs  due to abnormal liver function tests, see Section  13.3.2 and Section  13.3.3, respectively. 
b Glucose will be obtained after an 8 -hour f a st at Visit 1 and at any unscheduled visit.  
c At the discretion of the investigator.  
d    Only female subjects who have experienced menarche will have urine hCG; if the urine hCG test is 
positive confirm with serum hCG.  
Investigators must document their review of each laboratory safety report. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 126  
Physical Examinations (Section 6.3.4) 
Refer to the SoE (Section  13.1) for the timing and frequency for full and brief physical 
exam
inations, as well as height and body weight.  
A complete physical examination will include, at a minimum, assessments of the skin, 
cardiovascular, respiratory, gastrointestinal, neurological systems and Tanner staging 
(Section  13.5) . Height and body weight will also be measured and recorded. The s ubject 
should be dressed in light clothing and without shoes when the body weight is being measured.  
A brie
f physical examination will include, at a minimum, assessments of the skin, 
cardiovascular, respiratory, and gastrointestinal systems. 
Investigators should pay special attention to clinical signs related to previous serious 
illnesse s. 
  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: VPED -103 Amendment 2 30 August  2023  
Page 128 a For subjects participating in the pharmacodynamic substudy, Visit 2 (Day - 1) and Visit 6 (Day 8) are only required for 
subjects undergoing gastric pH monitoring if clinically indicated at select sites. pH monitoring will be conducted on 
Day -1 for 24 hours and on Day 7 for 24 hours. pH probes would be placed on Days -1 and 7 and removed on Days 1 
and 8.  
b At an unscheduled visit, the following procedures are to be completed with additional procedures at the investigator’s 
discretion: a brief physical examination, vital sign measurements, concomitant medication assessment, AE assessment, 
and clinical laborator y tests. If the visit results in premature termination, then all procedures outlined for the final visit 
should be performed.  
c Informed consent will be signed by the subject’s legally authorized representative prior to any activity in the study. Subject assent (if applicable) may be obtained as required per site guidelines.  
d A complete physical examination will be performed at screening (at minimum, assessment of skin, cardiovascular, respiratory, gastrointestinal, neurological systems and Tanner staging) . A brief physical examination will be performed 
at other visits (at minimum, assessment of skin, cardiovascular, respiratory, and gastrointestinal systems). Interim physical examinations may be performed at the discretion of the investigator, if necessary, to evaluate AEs or clinical laboratory abnormalities.  
e Vital signs will include systolic and diastolic blood pressure, pulse rate, respiratory rate, and temperature.  
f Height collected only at screening.  
g Hepatitis B surface antigen, hepatitis C virus antibody, and HIV type 1 and 2 antibodies.  
h Clinical laboratory testing will include hematology, serum chemistry, and urinalysis (if deemed necessary by the PI). Blood draws should follow vital signs or electrocardiograms.  
i Only female-born subjects who have reached menarche, will require guidance on avoidance of pregnancy and urine or serum hCG; if urine hCG is positive, confirm with serum hCG.  
j Single 12 -lead electrocardiogram recordings will be made after the subject has been in the supine position for at least 5 
minutes at screening. A pediatric cardiologist will interpret the ECG for eligibility and any abnormality. A single repeat measurement is permitted at screening for eligibility determination after the read by a pediatric cardiologist. 
Assessm ents should include comments on whether the tracings are normal or abnormal (if abnormal, whether clinically 
significant or not clinically significant). An ECG will be collected at the final visit and interpreted by a pediatric 
cardiologist.  
k Subject will be randomized to study treatment after all eligibility criteria have been met.  
l Study drug will be administered in the clinic on Days  1, 7, and 14. Study drug should be taken every day between 7 and 
10 am preferably prior to eating any breakfast or food.  Study drug for at home administration will be dispensed on Day 
1 (to be taken on Days 2 to 6) and Day 7 (to be taken on Days 8 to 13). At home, parents/caregivers will administer study drug to subjects. Clinic staff will review instructions with parents/LARs for administering study drug at home and completing the Study Drug Reminder Card. Phone call reminders may be conducted as required.  
m Blood samples for PK analysis of vonoprazan in plasma will be collected on Days 7 and 14. On Day 7 days, one pre -
dose sample will be collected prior to the morning administration of vonoprazan along with two additional samples 
collected after drug administration: one between 0.5 to 1.5 hours post -dose and one between 2.5 to 3.5 hours post -dose. 
On Day 14 days, one pre -dose sample will be collected prior to the morning administration of vonoprazan along with 
two additional samples collected after drug administration: one between 1 to 2 hours post -dose and one between 3 to 4 
hours post -dose. The exact time of each pharmaco kinetic sample should be recorded in the source and eCRF.  
If a subject terminates early, an attempt should be made to collect one blood sample if it can be collected within 24 
hours following the last dose of study drug. The exact date and time of the ear ly termination sample must be recorded.  
n Collection of pretreatment events will start after the informed consent form has been signed. Adverse events will be 
assessed from time of informed consent signing until the follow -up visit and should be followed u ntil they are resolved, 
stable, or judged by the investigator to be not clinically significant.  
 
 